Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †

Christine Rangger and Roland Haubner *

Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria; christine.rangger@i-med.ac.at
* Correspondence: roland.haubner@i-med.ac.at; Tel.: +43-512-504-80069
† This paper is dedicated to the 80th birthday of Prof. Horst Kessler.

Received: 20 December 2019; Accepted: 16 January 2020; Published: 30 January 2020

Abstract: This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.

Keywords: radiolabelled peptides; positron emission tomography; peptide receptor radiotherapy; oncology; metabolic stability; labelling strategies

1. Introduction

More than two decades ago, radiolabelled (DOTA\(^\circ\), Phe\(^\circ\), Tyr\(^\circ\)) octreotide (DOTATOC) was introduced for theranostics of patients with somatostatin expressing neuroendocrine tumours [1]. Only a few years later, the first clinical studies with the \(^{68}\)Ga-labelled analogue were carried out [2], paving the way for the development of a variety of different radiolabelled peptides and peptide analogues for the diagnosis and treatment of tumours. In this review, pros and cons of peptides compared to other radiopharmaceuticals like monoclonal antibodies and small molecular weight molecules, labelling strategies using radiohalogens as well as radiometals, and strategies to improve the stability of radiolabelled peptides are discussed. In the second part, the most prominent derivatives used for positron emission tomography (PET) and peptide receptor radiotherapy (PRRT), including peptides targeting somatostatin receptors (SSTR), integrins, chemokine receptors, or the prostate-specific membrane antigen (PSMA), are introduced and their imaging properties are described.

2. Peptides as Targeting Probes—Pros and Cons

Radiolabelled small peptides are the major class of radiopharmaceuticals used in the diagnosis and therapy of tumours. This can be explained by the fact that a great diversity of small peptides function as endogenous ligands in a variety of molecular processes during tumour development, growth, signal transduction, and dissemination, as well as that these compounds possess beneficial properties as targeting probes in nuclear medicine.

Compared to antibodies, they are not immunogenic and show fast diffusion and target localisation. Additionally, peptides can be modified, improving metabolic stability and adjusting favourable pharmacokinetics (e.g., see [3]). In contrast to small molecular weight compounds, peptides are more tolerant of modifications, allowing appropriate labelling. For example, chelating moieties for radiometallation are much easier to conjugate to peptides as to small organic structures.
without interfering with the binding affinity and pharmacokinetic properties. The same applies to modifications to optimise pharmacokinetics like the use of polyethylene glycol (PEGylation), the introduction of carbohydrates or other pharmacokinetic modifiers [3].

Because of the presence of endogenous enzymes for the degradation of peptides and proteins, the major disadvantage compared to small molecular mass probes could be the lower metabolic stability, which is why a variety of strategies exists to overcome this problem. These strategies include the introduction of unnatural amino acids, backbone cyclisation and modifications and are described in detail in the following chapter.

3. Improvement of Metabolic Stability

Peptides and proteins are essential endogenous components forming the human proteome. Thus, a variety of enzymes is found in blood and other tissue such as the liver and kidneys to process these compounds. These enzymes include exopeptidases to cleave N- and C-terminal amide bonds as well as endopeptidases, which cleave amide bonds within the molecule sequence.

A variety of strategies, not only in radiopharmaceutical chemistry, focus on the stabilisation of peptides and proteins. Here should be mentioned that protection from exopeptidases might be easier than from endopeptidases. A straightforward strategy for this approach is backbone cyclisation where the N-terminal end is conjugated with the C-terminal end of the peptide sequence. This has been successfully demonstrated with many radiopharmaceuticals targeting integrins. A variety of RGD-peptides—binding to integrin receptors—are based on the cyclic pentapeptide c(RGDfV), which shows high stability in vivo (for a review, see, e.g., [4]). For example, no metabolites of [68Ga]Ga-NODAGA-RGD (where NODAGA is 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid) were found in the blood and urine of patients over the whole observation period up to 1 h post-injection [5]. However, problematic might be that, due to cyclisation, the flexibility of the peptide is reduced which, in the case of the RGD-peptides, improved the target selectivity but can also negatively influence the affinity of the peptide. Thus, this approach cannot be seen as a general strategy to improve the metabolic stability of peptides. In some cases, modification of the N- and/or C-terminal end also allows protection from exopeptidases. Especially, if radiometallation for labelling is used, corresponding chelating moieties have to be introduced. In many cases, these systems are conjugated either directly or via a spacer to the N-terminal end, which might already increase stability against exopeptidases. The C-terminal modifications often include the formation of an amide (-CONH₂ or -CONHR) as found for, e.g., radiolabelled minigastrin and bombesin derivatives [6,7].

Reduction of the carboxylate to an alcohol function is applied with Tyr⁴-octreotide, where the C-terminus includes a threoninol instead of a threonine [8].

Another relatively easy strategy for stability improvement towards endopeptidases is based on the use of D-amino acids or unnatural amino acids such as naphthylalanine, phenylglycine, norleucine, and cyclohexylalanine as found, e.g., by Murza et al. [9] or Klingler et al. [10]. In many cases, a combination of N/C-terminal modification with stabilisation via D-amino acids or unnatural amino acids is used as described for Tyr⁴-octreotide or different RGD-derivatives. The sequence of Tyr⁴-octreotide includes N-terminal D-Phe and D-Trp at position 4 in combination with the C-terminal threoninol, as already referred to above. For a variety of RGD-based tracers like Galacto-RGD, backbone cyclisation is combined with the introduction of D-Phe in position 4 of the peptide sequence [11], which, besides stabilisation, also results in the RGD-sequence being in the γ-turn position which is necessary for high integrin αᵩβ₃ affinity [12]. Some endopeptidases recognise special amino acids, e.g., trypsin is specific for Arg and Lys and chymotrypsin for Trp, Tyr and Phe. Thus, the replacement of these amino acids in the corresponding sequence will be of particular benefit. Obviously, not all amino acids in a sequence can be replaced either by the corresponding D-amino acid or by an unnatural amino acid without influencing the binding affinity. Sometimes the essential amino acids of a peptide sequence are already known; if not, a so-called “alanine scan” (for details see, e.g., [13]) may supply this information.

Other stabilisation approaches focus on the modification of amide bonds, which are the cleavage site of endopeptidases. These modifications range from methylation/alkylation of the nitrogen to
complete replacement of this moiety, resulting in a variety of peptide bond isosteres [14]. Usually, such modifications are chemically much more complex than the introduction of unnatural amino acids and can result in drastic changes to the peptide properties. Depending on the modification carried out, it includes higher flexibility of the modified amide bond and changes in electron densities and thus, changes in the hydrogen bridge donor/acceptor character. This might alter the peptide structure and could influence the binding affinity as well as the pharmacokinetics. The formation of such peptide bond isosteres is often starting with the synthesis of the corresponding pseudo dipeptide, which will be incorporated in a second step into the peptide sequence. Especially the synthesis of such dipeptide derivatives including complex (e.g., side chain functionality containing) amino acids can result in difficult multistep synthesis routes and determination of the binding affinity of the final peptide after modification is a prerequisite. Nevertheless, the introduction of such peptide bond isosteres has already been successfully applied to stabilise radiolabelled neurotensin analogues [15].

4. Labelling Strategies

Two general labelling strategies for peptides can be distinguished: Labelling via radioactive halogen isotopes like fluorine-18, bromine-76, iodine-124, iodine-131, and astatine-211 and labelling via radiometals like copper-64, gallium-68, zirconium-89, yttrium-90, technetium-99m, indium-111, and lutetium-177 (for physical characteristics of the different isotopes, see Table 1). Due to the different characteristics, labelling of the first class focuses on direct labelling or labelling via prosthetic groups, whereas labelling of the latter is carried out via chelating systems coupled with the peptides. Also, most recently, strategies to use fluorine-18 with chelating systems have been introduced. Here we want to summarise some standard labelling protocols, describe the most common prosthetic groups as well as new alternative labelling strategies. With the exception of radioiodine, only labelling procedures for isotopes used with PET or therapeutic approaches will be included.

Table 1. Selected physical parameters of the discussed isotopes for positron emission tomography (PET) imaging and therapy (available from The Lund/LBNL Nuclear Data Search: http://nucleardata.nuclear.lu.se/toi/; Laboratoire National Henri Becquerel: http://www.lnhb.fr/nuclear-data/nuclear-data-table/).

| Isotope | Half-Life [h] | Decay Mode | Energy (keV) |
|---------|---------------|-------------|--------------|
|        |               | Halogens    |              |
|        |               | β− (96.9%)  | β−: 633.9    |
|        | [18F]         | EC (3.1%)   |              |
|        | [76Br]        | β− (54%)    | β−: 4963     |
|        | [124I]        | β− (23%)    | β−+EC: 3160  |
|        | [131I]        | β− (100%)   | β−: 970.8    |
|        | [211At]       | α (41.8%)   | α: 4000–8500 |
|        |               | EC (58.2%)  |              |
|        | Radiometals   |              |              |
|        | [64Cu]        | β− (17.8%)  | β−: 653      |
|        | [68Ga]        | β− (38.4%)  | β−: 579      |
|        | [89Zr]        | EC (43.5%)  |              |
|        | [90Y]         | β− (88.9%)  | β−: 1899.1   |
|        | [127I]        | EC (11.1%)  |              |
|        | [172Lu]       | β− (23%)    | β−: 902      |
|        | [225Ac]       | β− (100%)   | β−: 2279     |
|        |               | α (100%)    | α: 5800–8400 |

* electron capture.
4.1. Halogens

4.1.1. Fluorine

Fluorine-18 is the most common radioisotope for PET. It combines with 109 min, an appropriate half-life with high positron emission (97%), and suitable positron energy (0.634 MeV) and can be produced easily from enriched 18O-water with every routine cyclotron.

For small molecular mass compounds like [18F]FDG, a frequently applied strategy is direct labelling via nucleophilic substitution. This approach is, in many cases, not suitable for peptides due to the harsh reaction conditions and potential formation of [18F]HF in the presence of acidic protons. Therefore, although in some cases direct labelling can be applied (see, e.g., [16]), a general strategy for 18F-labelling of peptides is based on prosthetic group labelling and uses the different functional groups of the corresponding amino acids like thiols, carboxylates, alcohols, and amines in the peptide sequence. Thus, 18F-labelling strategies focusing on alkylation, acylation, and amidation are described [17,18].

Acylation of an amino function in the peptide sequence (N-terminal or ε-amino function of lysine) is a widespread approach of introducing an activated ester as a prosthetic group. The most prominent derivative is N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). Based on the three-step synthesis described by Vaidyanathan and Zalutsky [19], a variety of modifications has been suggested to optimise synthesis and radiopharmaceutical yield [20]. For example, Wüst et al. [21] started with the fluorination of 4-N,N,N-trimethylammonium ethyl benzoate followed by the hydrolysis of the ethyl ester and subsequent activation using O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TSTU). Another prosthetic group for labelling peptides is 4-nitrophenoxy-2-[18F]fluoropropionate [11], which is, due to its aliphatic character, less lipophilic than the benzoic acid derivative. As for a variety of prosthetic groups using acylation for conjugation with the peptide, again, the synthesis includes labelling of the corresponding precursor, hydrolysis of the ester and subsequent activation for acylation. In general, this strategy needs at least one HPLC separation step of the final product; sometimes even intermediates have to be isolated via HPLC, which makes these approaches very complex and time consuming.

The major obstacle in developing an easy 1-step procedure is found in the reactivity of the activated ester function, which interferes with the fluorination reaction [20]. Regardless of that, some 1-step procedures have been reported, including the synthesis of N-succinimidyl-4-([18F]fluoromethyl)benzoate [22] and [18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ([18F]Fpy-TFP), a nicotinic acid derived active ester [23]. For the latter, labelling yields have been between 60 and 70% at low temperatures with almost quantitative conjugation, making this approach an interesting alternative for a variety of peptides. Other strategies to obtain 1-step procedures use the high affinity of fluorine to boron and silicone and introduce silicone fluoride acceptor (SiFA) groups [24] for labelling the prosthetic group. Relying on an isotopic exchange, labelling is straightforward. However, the disadvantage is the high lipophilic property of the SiFA group, which can have a negative influence on the pharmacokinetics of especially small peptides.

In the last decades, other options for 18F-labelling of peptides have been reported. These consist of conjugation via “click chemistry”, oxime and hydrazone formation, or the use of maleimide as the thiol reactive group (Michael addition) (for a review, see [20]). Click chemistry, the 1,3-dipolar cycloaddition of an alkyne and an azide at ambient temperature, was first used in radiochemistry to produce 99mTc(CO)5-labelled radiopharmaceuticals [25]. Recently, this approach was also introduced for 18F-labelling. 18F-labelled alkynes [26] as well as azides [27] have been reported as prosthetic groups for the labelling of correspondingly modified peptides (e.g., via 3-azido propionic acid or propargylglycine) and demonstrated the fast and regioselective Cu-catalysed formation of the corresponding triazole. More recent applications avoid the use of Cu(I) catalyses and are focused on strain-promoted Cu-free click chemistry with aza-benzocyclooctyne derivatives as constrained dipolarophiles [28,29]. Nonetheless, the elimination of the Cu(I) is paid by an increased lipophilic character of the resulting radiopharmaceutical, which may negatively influence the pharmacokinetics.
Another approach introduces aminooxy-functionalised peptides allowing regioselective labelling using aldehydes and ketones as prosthetic groups. The most commonly used $^{18}$F-labelled aldehyde is 4-$^{18}$F-fluorobenzaldehyde [30]. This strategy has also been used to label peptides: for example, Poethko et al. [31] successfully labelled multimeric RGD-peptides modified with an aminooxy function. Interestingly, also 2-hydrizinonicotinic acid (HYNIC)-modified peptides allow reactions with 4-$^{18}$F-fluorobenzaldehyde via the formation of a hydrazone, which has been demonstrated with HYNIC-Tyr3, Thr8-octreotide [32]. Radiolabelled carbohydrates could be also an interesting prosthetic group because they would not only allow $^{18}$F-labelling of the peptide but also increase the hydrophilic character, which is often a prerequisite for favourable pharmacokinetics. In this regard, it has been proven that $^{18}$F-FDG (which is in the open form an aldehyde) can be conjugated to peptides via oxim formation. Critical is that the routinely produced $^{18}$F-FDG includes high amounts of free glucose interfering with the labelling reaction, thus a HPLC separation has to be introduced to get acceptable labelling yields [33,34]. Other approaches introduced modified carbohydrates like thiosulfonate derivatives, allowing formation of disulfide bridges with Cys in the peptide sequence [35], or an azide derivatised FDG, which can be conjugated via click chemistry [36], as discussed earlier.

The chemoselectivity of thiol groups, as found in the amino acid Cys, is also exploited using maleimide derivatives as prosthetic groups (for a review, see [20]). The syntheses of the described derivatives are very complex and include, commonly, 3 to 4 steps [37], or start with another prosthetic group (e.g., 4-$^{18}$F-fluorobenzaldehyde or $^{18}$F-SFB) [38,39], which is bound in a subsequent step to a variety of maleimide derivatives. It is questionable if the advantage of the high regioselectivity compensates the high complexity of the synthesis route. Strategies that are more straightforward include isotopic exchange reactions with boron- and silicone-containing maleimide derivatives [40,41] or conjugate the maleimide group to the peptide and use thiol-containing prosthetic groups [42,43].

An alternative strategy, which allows direct labelling of peptides and proteins, is based on the introduction of aluminium fluoride species “AlF” (for an overview, see [44]). This approach uses the strong binding of fluorine to aluminium and allows labelling via chelating systems, according to the labelling with radiometals. Several chelating moieties have been studied, of whom NOTA derivatives might be the best choice, yet [44]. A variety of peptide structures have been labelled using this method. Labelling is straightforward with reaction times of approximately 15 min at 100 °C (see, e.g., [45]). Critical might be the stability of the complexes. However, initial clinical data with RGD-peptides [46,47] and octreotide derivatives [48] demonstrated good delineation of the tumours with low activity in the bone (see also below).

Due to the mild reaction conditions of the SiFA approach, this strategy was not only used for the labelling of prosthetic groups but also for direct labelling of peptides modified with corresponding SiFA groups [49]. To improve the hydrophilic character of such modified peptides, hydrophilic modifiers and the SiFAlin building block have been introduced. The resulting $^{18}$F-SiFAlin-Glc-Asp2-PEG3-TATE could be produced in approximately 10 min at ambient temperature in good radiochemical yield.

4.1.2. Bromine

Bromine-76 is a positron emitter (54% positron emission) with a half-life of 16.2 h, which is comparably long related to the routinely-used PET isotopes, enabling the use in tracers with a slower elimination from the body. Labelling can be done in analogy to iodine using the electrophilic substitution approach and tyrosine in the peptide sequence (see also below). Oxidation can be carried out via oxidising reagents like chloramine T [50] or via corresponding enzymes [51]. In addition, prosthetic group labelling strategies can be used, including Bolton Hunter labelling [52] or approaches with oxidative substitution and trialkyl tin leaving groups, as found in $^{18}$F-N-succinimidyl p-(4-tri-n-butylstannyl)benzoate [53]. Recently, an electron rich 2,6-dimethoxybenzene moiety was introduced, which can easily attach bromine-76 at its activated position ortho to the methoxy group without the need of a leaving group. Thus, $^{18}$F-N-succinimidyl 2,6-dimethoxybenzoate can be either used.
for direct labelling through pre-conjugation or as a 76Br-labelled prosthetic group for indirect labelling, which has been successfully demonstrated by conjugation to the amino function in the cyclic peptide c(RGDDyK) [54].

The main advantage of bromine-76 might be the suitable long half-life, making it an interesting alternative for some applications, but a problem is that a potential radiocatabolite might be radiobromide, which is very slowly excreted, and is distributed in the extracellular space, resulting in high background activity. Thus, careful tracer design and optimisation is required to avoid this obstacle in the introduction of bromine-76 for PET applications [55].

4.1.3. Iodine

A variety of radioactive iodine isotopes is available. These range from iodine-125 for preclinical research and RIA applications over iodine-123 for single-photon emission tomography (SPECT) to iodine-124 for PET and iodine-131 for therapeutic approaches. Labelling strategies are equivalent for all isotopes (for a review, see, e.g., [56]). The easiest way to label peptides is based on the electrophilic substitution of the activated protons in position 2 and 5 of the phenol ring of tyrosine moieties in the peptide sequence. Hence, the iodide in sodium iodide is oxidised to the iodine cation (I+). For oxidation, different strategies are available. Typical oxidation reagents are chloramine T, chloramine T bound to a resin (Iodobeads®) or Iodogen®. The latter two methods have the advantage that, under standard labelling conditions, the separation of the insoluble oxidation reagent is straightforward. Problems can arise if oxidation sensitive amino acids like Cys and Met or His, which can also be iodinated at the ring system, are included in the peptide sequence. In such cases, different options are available: (A) Separation of the I-species from the oxidising reagent before incubation with the peptide (which might result in low labelling yields). (B) The use of peroxidases for the oxidation, which are milder oxidation reagents (but might have the disadvantage that the enzyme itself will be labelled which is why a subsequent separation of the protein from the desired radiolabelled peptide is needed). (C) The use of prosthetic group labelling. From the presented options, (A) and (B) are only of advantage for Cys and Met. The latter strategy can be used in any case and is the approach of choice if no tyrosine is present in the peptide sequence of interest.

The most common prosthetic group for iodination is the Bolton Hunter reagent [N-succinimidyl-3-(4-hydroxyphenyl)propionate] [57]. This activated ester is commercially available in the iodinated form, at least for iodine-125. Regardless, the Bolton Hunter reagent can be easily iodinated in-house using the same procedures described for the labelling of tyrosine. Due to the activated carboxylate, the iodinated Bolton-Hunter can be conjugated to any amino function in the peptide sequence—N-terminally as well as on the ε-amino function of lysine. If a regioselective position is desired, potential additional amino functions have to be protected. In many cases, labelling via the electrophilic substitution results in good labelling yields but even better labelling yields might be provided by using N-succinimidyl-3-(tri-n-butylstannyl)benzoate as the prosthetic group [58]. Compared with the phenol derivative, an additional advantage is the higher metabolic stability of the resulting C-I bond of the benzoate derivative because the latter can be de-iodinated by endogenous enzymes involved in the metabolism of thyroid hormones.

4.1.4. Astatine

Astatine-211 (half-life 7.2 h) is an α-particle emitting radiohalogen (range approx. 25–100 μm; energy approx. 4–8.5 MeV), which was already suggested for targeted radiotherapy of small tumour clusters or even isolated disseminated tumour cells more than 40 years ago [59]. Nonetheless, initial clinical trials with a 211At-labelled chimeric monoclonal antibody (mAb) were not described before this millennium [60]. In this case, prosthetic group labelling was carried out using N-succinimidyl-3-(tri-n-butylstannyl)benzoate as precursor [61]. Since this clinical study, not many more reports were published. In 2009, one additional study reports on 211At-MX35 F(ab′): for the treatment of ovarian cancer with a long-term follow-up presented most recently [62,63]. In contrast to Zalutsky et al., another group reported on 211At-labelling via a direct procedure on an ε-lysyl-3-(trimethylstannyl)benzamide modified immunoconjugate [64].
Theoretically, a variety of labelling strategies might be possible because of the ambivalent character of astatine—being either halogen or metalloid. These involve halogen exchange, dediazoniation, electrophilic aromatic substitution, and demetallation on one hand, and complex formation on the other [65]. Due to the soft-cation character of astatine, chelators with soft-donor atoms like sulphur are superior to chelators with hard-donor atoms, as found in diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). This could be demonstrated by comparing the complex formation constants of a variety of chelators [65,66]. Regardless of that, in vivo stability of such complexes seems low, as demonstrated in studies with $^{211}$At-labelled sulphur-containing calix[4]arene [67]. Thus, most efforts are focused on the development of labelling strategies based on the formation of carbon/astatine bonds [65]. Among the listed approaches, demetallation reactions seem the most appropriate for $^{211}$At-labelling of peptides and proteins. As already discussed above, tributyl- and trimethylstannyl groups are preferably used as leaving groups. In most cases, labelling via prosthetic groups, especially $N$-succinimidyl astatobenzoate (SAB), is carried out whereas direct labelling was also described. Due to its high energy, the LD$_{50}$ of $^{211}$At-astatide is low [68] and great emphasis has to be laid on the in vivo stability of corresponding radiopharmaceuticals. Most recently, a $^{[211}$At$]^{-}$astatobenzamido-labelled PSMA derivative demonstrating specific prostate cancer cell kill in vitro and in vivo has been introduced [69]. Again, some dehalogenation was observed but the major concern was the late nephrotoxicity due to $\alpha$-particle irradiation of the tracer bound to receptors in the kidneys.

Boron clusters have been considered for labelling with astatine-211 because the boron/astatine bond is more stable than the carbon/astatine bond. Fab fragments modified with a variety of boron clusters (e.g., nido-carboranes and closo-decaboranes) allowed $^{211}$At-labelling in yields up to 75% within 10 min and $^{211}$At-labelled Fab fragments revealed high in vivo stability [70]. However, the introduced boron cluster negatively influenced the pharmacokinetic of the Fab fragment with increased activity found in some tissue, including the liver.

4.2. Radiometals

4.2.1. Copper

The decay characteristics of copper-64 [half-life: 12.7 h; $\beta^{-}$: 0.653 MeV (17.8%); $\beta^{-}$: 0.579 MeV (38.4%)] allow PET imaging as well as targeted radiotherapy. Moreover, the long half-life enables the use of peptides and especially proteins with longer blood circulation times in combination with PET.

Copper exists in several oxidation states, and for radiopharmaceutical approaches, copper (II) possesses the optimal characteristics, making copper (II) complexes the most attractive area for research in clinical radiopharmacy. Copper (II) is a d$^9$ metal and coordinates preferably with amines, imines, and bidentate ligands such as bipyridine [71]. Due to the intensive use with other metals like gallium-68, lutetium-177, or yttrium-90, 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) was also studied as a bifunctional chelator for labelling with copper-64. Nonetheless, the in vivo stability of such complexes is suboptimal with transmetallation to endogenous proteins (see, e.g., [72,73]). Slightly higher stability against transchelation is found if 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) is used for complexation, as shown with $[^{64}$Cu$]Cu$-TETA-OC [74]. Compared to DOTA and TETA, additional cyclen and cyclam derivatives revealed improved stability in vivo (for an overview, see [75]). Recently, 1,4,7-triazacyclononane-$N,N',N''$-triacetic acid (NOTA) derivatives were investigated for the complexation of copper-64 and in several studies, this chelating system demonstrated good performance with high labelling yields and improved stability in vivo [76–78].

Another way to improve metabolic stability is focused on cross-bridged macrocyclic chelating agents. The most prominent might be 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) [79]. The major disadvantage of this chelator is the harsh labelling conditions, which it makes only suitable for heat-insensitive peptides [75]. There are a variety of optimisations for the labelling conditions including the introduction of a propylen instead of the ethylene cross-bridge (PCB-TE2A; [75]) or the use of phosphonate instead of the carboxylate
groups (CB-TE2P; [80]). Especially with the latter, labelling can be carried out at room temperature. Most recently, Dos Santos et al. [81] studied different cross-bridged and non-bridged cyclam derivatives conjugated to PSMA for the use with copper-64 and found the best performance of a non-bridged derivative. It was argued that kinetic inertness against demetallation might be more crucial than thermodynamic inertness in vivo and that the overall configuration of the Cu(II)-complex has to be considered.

In addition, sarcophagine-based chelators (hexaazamacrocyclic cage type ligands like SarAr, AmBaSar, diamSar, and BaBaSar) are studied as bifunctional chelators for labelling with copper-64 [75,82]. These nitrogen-rich chelators allow labelling within a few minutes at room temperature and the resulting complexes show excellent in vivo stability as well as strong resistance to dissociation in vitro (for details, see [82]). A disadvantage might be the lipophilic character, which leads to the formation of cationic or natural Cu-complexes. Thus, derivatives including carboxylic functions like BaBaSar have been introduced. Recently, $^{68}$Cu-Cu-BaBaSar-RGD2 was studied in non-human primates, demonstrating high metabolic stability and predominantly renal elimination with highest activity concentration in kidneys and urinary bladder wall [83].

4.2.2. Gallium

Since $^{68}$Ge/$^{68}$Ga-generators became available, there has been a great interest in the development of $^{68}$Ga-labelled peptides for PET imaging. Besides the broad availability (independent of a cyclotron in-house or nearby), also the straightforward methods for the labelling of peptides and the successful introduction of $[^{68}$Ga]Ga-DOTATOC for imaging SSTR expression in clinical routine were the basis for this widespread interest. Meanwhile, the daily demand of corresponding radiopharmaceuticals increased so that, in some cases, the supply via generator hampers due to the limited activity that can be eluted. Thus, there are great attempts to establish cyclotron-based production routes (for an overview, see [84]) which might overcome this problem, at least where a cyclotron is available.

In general, two types of bifunctional chelator can be distinguished for complexation of gallium-68: acyclic and cyclic derivatives. Acyclic chelators include DTPA, desferrioxamine B (DFO), Hxdedpa, 1,2-dimethyl-3,4-hydroxypyridinone ( deferiprone), and hydroxybenzyl ethylenediamine (HBED) (for more details, see, e.g., [82]). Due to the use with a PSMA targeting radiopharmaceuticals, meanwhile, $N,N'$-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-$N,N'$-diacetic acid (HBED-CC) might have become the most well-known acyclic derivative for labelling with gallium-68 [85]. More commonly used are macrocyclic derivatives. Initially, DOTA was the chelating moiety of choice but the atom radius of gallium-68 is not optimal for the complexation, which leads to a hexacoordinated complex not including all carboxylate functions. The nine membered ring structure of NOTA and its derivatives is better suited for gallium-68, resulting in higher complex stability and already allows labelling at room temperature. This could be proven, e.g., with $[^{68}$Ga]Ga-NODAGA-RGD, which was more stable in vivo than $[^{68}$Ga]Ga-DOTA-RGD [86]. Triazacyclononane-phosphinic acid (TRAP) is also a nine membered ring but includes phosphinic acid moieties. The complex-forming constant is high, allowing labelling at room temperature with low amounts of labelling precursor [87]. Due to the presentation of three terminal carboxylate functions, it is possible to use this chelator as a scaffold for multimeric tracers. Notni et al. [88] presented a $[^{68}$Ga]-labelled trimeric RGD-containing tracer with good imaging performance. If only monomeric derivatives are of interest, 1,4,7-triazacyclononane-1,4-bis[methylene(hydroxymethyl)- phosphinic acid]-7-[methylene(2-carboxyethyl) phosphinic acid] (NOPO) is an alternative to TRAP where the phosphor group of two arms is oxidised to phosphonic acid [89]. Another class of bifunctional chelator is 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine (AAZTA) with a N3O complex geometry. In contrast to the before-mentioned nine membered ring systems, they combine a macrocyclic 1,4-diazapam ring with a free acrylic arm [90]. Recently, also siderophores, cyclic DFO derivatives used especially by fungi for iron complexation, have been introduced for complexation of gallium-68 [91,92]. Depending on the derivative used in analogy to the TRAP/NOPO system, monomeric as well as multimeric radiopharmaceuticals can be produced.
4.2.3. Zirconium

Zirconium-89 is a transition metal of group IVB. The decay proceeds via electron capture (77%) and positron emission (23%) with an Emax of the positron decay of 902 keV and a half-life of 3.3 days. The comparable long half-life makes it an ideal isotope for the use with mAbs and mAb fragments. Thus, developments are primarily focused on immuno-PET applications introducing a variety of [\(^{89}\)Zr]-labelled antibodies including \([^{89}\text{Zr}]{\text{Zr}}\)-trastuzumab (anti-HER2 mAb) [93], \([^{89}\text{Zr}]{\text{Zr}}\)-cetuximab (block EGFR activation) [94], and \([^{89}\text{Zr}]{\text{Zr}}\)-bevacizumab (block VEGF-induced tumour angiogenesis) [95]. Of disadvantage might be the high gamma emission at 909 keV, which limits the radioactive dose that can be administered.

The most commonly used chelating systems are based on DFO, which conjugates \(\text{Zr}^{4+}\) via the three hydroxamate moieties of the compound [96]. Since \(\text{Zr}^{4+}\) is preferable, octa-coordinated DFO seems not to be the optimal chelating system. This instability could be shown in in vivo studies where some release of the metal with up to 10% ID/g of the radionuclide was found in the bone [97]. Despite this disadvantage, a variety of bifunctional chelators based on DFO have been developed. They can be divided into two groups: derivatives binding randomly preferred on amino functions of lysine moieties in the sequence or derivatives binding side specifically via, e.g., thiol-reactive groups or click chemistry (for a review, see [97]).

Improvement of complex stability is also achieved by adding an additional hydroxamate group [98]. The resulting DFO*-pPhe-NCS-conjugated \([^{89}\text{Zr}]{\text{Zr}}\)-trastuzumab showed reduced bone, spleen, and liver uptake in tumour-bearing nude mice compared to the \([^{89}\text{Zr}]{\text{Zr}}\)-trastuzumab conjugated with commercially available DFO [99]. It is known that a macrocyclic system improves complex stability; thus, some attempts are also made to develop such structures for the complexation of zirconium-89. These strategies include the introduction of natural siderophores like fusarine C (FSC) and their derivatives [100], cyclic compounds containing 1-hydroxypyridin-2-one groups (HOPO) [101], and DOTA [102]. The use of DOTA for \(\text{Zr}^{4+}\) is especially surprising because this system offers only four o xo-coordination sites; the remaining coordination sites are covered by nitrogen atoms. Despite that, the resulting complex shows high in vitro and in vivo stability. Of disadvantage are the drastic labelling conditions (95 °C, 1 h) which make the use with antibodies problematic. To overcome this problem, it is discussed to use DOTA-derivatives as prosthetic groups and label the antibody before conjugation to the biomolecule [97].

Altogether, there are many alternative approaches studied, but all of them have some disadvantages; thus, further developments are needed to find the optimal bifunctional chelator for zirconium-89. However, in most clinical settings, mAbs modified with DFO are still used because this bifunctional chelator is readily available, and the eventual release of zirconium from the chelator seems not to influence imaging quality.

4.2.4. Yttrium, Lutetium

Yttrium-90 (half-life 2.7 days) and lutetium-177 (half-life 6.7 days) are both \(\beta\)-emitting isotopes used for endoradiotherapy. In contrast to yttrium-90, lutetium-177 also emits \(\gamma\)-radiation, and its distribution can be monitored using SPECT. For lutetium-177, \(E_{\text{beta}}\) max is 0.5 MeV and 2.3 MeV for yttrium-90, resulting in a maximum tissue penetration range of 1.5 and 12 mm, respectively [103].

Coordination chemistry and properties of \(\text{Y}^{3+}\) and \(\text{Lu}^{3+}\) are comparable. Both prefer 8 to 9 hard ligand donor atoms like carboxylate oxygen or amine nitrogen for coordination, resulting in antiprismatic or monocapped square antiprismatic geometries [82]. The current standard chelator for complexing these isotopes is DOTA. An accepted disadvantage of DOTA-labelling is that, due to the slow labelling kinetics, sufficient labelling yields are only achieved with enhanced temperatures [82]. An alternative for DOTA would be \(2\)-(p-isothiocyanatobenzyl)-cyclohexyldiethylentriamine pentaacetic acid (CHX-A*-DTPA), which showed enhanced radiolabelling kinetics [82]. Nonetheless, labelling with yttrium-90 or lutetium-177 often requires mild heating (>37 °C) and reaction times between 30 and 60 min to achieve reasonable labelling yields.

Attempts have been made to develop chelator systems allowing labelling under so-called “kit conditions” (room temperature, pH 5–6). Recently, \(6\)-Amino-6-(5-methoxy-5-oxopentyl)-1,4-
diacepine-tetraacetate (AAZTA-5) was introduced and demonstrated that by conjugation to TOC labelling with lutetium-177 in high yield was possible with low tracer amounts in less than 10 min at room temperature at a pH between 4.5 and 5.5 [104]. Stability in human serum was acceptable even after 7 days of incubation. Another study investigated N,N'-bis(6-carboxy-2-pyrididymethyl)ethylenediamine-N,N'-diacetic acid (H₂octapa) as an acyclic chelator exhibiting significant thermodynamic stability and kinetic inertness with lutetium-177 [105]. Moreover, H₂octapa-trastuzumab could be labelled with lutetium-177 at room temperature within 15 min in high radiochemical yield and was found to be superior to DOTA-trastuzumab. It is assumed that this chelator shows comparable properties if labelled with yttrium-90, but this is not yet proven. Another macrocyclic chelator system discussed for labelling with yttrium-90 and lutetium-177 is [4-[2-(Bis-carboxy-methylamino)-5-(4-thiocarbonylaniline)]pentyl]-7-carboxymethyl[1,4,7]triazonan-1-yl]acetic (3p-C-NETA-NCS) [106]. Again, 3p-C-NETA-trastuzumab can be labelled at room temperature in short reaction times in high radiochemical yield but, in contrast to the aforementioned, this works for both lutetium-177 and yttrium-90.

Despite these promising data, none of the alternative bifunctional chelators are applied in ⁹⁰Y- or ¹⁷⁷Lu-labelled radiopharmaceuticals in clinical routine, yet this might change if more sensitive mAb or other proteins become interesting for endoradiotherapeutic applications.

4.2.5. Actinium

Actinium-225 (half-life 10.0 d) decays by emission of net 4 α- (energy between 5.8 and 8.4 MeV) and 2 β-particles (energy between 198 and 659 keV) to bismuth-209 and is, thus, recognised as a potential isotope for the endoradiotherapy of cancer.

Actinium isotopes are typically found as ³⁺ cations. Due to the large ionic radius (112 pm) large polynadate chelators should be the compounds of choice [107]. As for other radioisotopes, macrocyclic chelators seem to be superior. There is a variety of chelators studied for complexation of ²²⁵Ac. These include 1,4,7,10,13,16-hexaacrylohexadecane-N,N',N'',N'''-hexaacetic acid (HEHA) [108] and DOTA as well [109]. However, HEHA-mAb-constructs did not internalise and released actinium-225 from the complex, resulting in liver and bone accumulation [110]. In contrast, [²²⁵Ac]Ac-DOTA-mAb-conjugates were more stable in vivo and formed internalising immune complexes with the corresponding antigen [110]. As already mentioned, a disadvantage is the elevated temperature needed for high labelling yields, which limits the application of this chelator for sensitive biomolecules such as antibodies [107]. Again, the use of [²²⁵Ac]Ac-DOTA-derivatives as prosthetic groups is suggested to solve this problem [111]. Recently, N,N'-bis[(6-carboxy-2-pyrididil)methyl]-4,13-diaza-18-crown-6 (Hmacropa) and its bifunctional analogue Hmacropa-NCS have been proposed [112]. This chelator allows labelling with actinium-225 at room temperature within several minutes at submicromolar precursor concentrations. ²²⁵Ac-labelled trastuzumab as well as [²²⁵Ac]Ac-macropa-RPS-070 (targeting PSMA) showed high in vivo stability and good tumour targeting properties with low activity found in other organs, making it an interesting alternative in complexing actinium-225.

A summary of the different chelators which are used for labelling with radiometals and the corresponding labelling conditions are presented in Table 2.

| Isotope  | Chelator         | Labelling Conditions | Reference |
|----------|------------------|----------------------|-----------|
| [⁶⁴Cu]   | CB-TE2A a        | 95 °C, 1 h           | [113]     |
|          | CB-TE2P         | RT                   | [80]      |
|          | DOTA b          | RT, 15 min           | [114]     |
|          | NOTA c          | RT, 45 min           | [115]     |
|          | PCB-TE2A        | RT                   | [75]      |
|          | TETA d          | RT, 45 min           | [74]      |
|          | Sarcophagine-based chelators | RT, within min | [75,82] |
5. Clinically Investigated or Routinely Used Radiolabelled Peptides

A great variety of peptides have been explored for use as radiolabelled probes for tumour diagnosis and treatment (see, e.g., [123,124]). Examples are peptides targeting SSTR, PSMA, integrins, chemokines, urokinase-type plasminogen activator receptors (uPAR), cholecystokinin receptors (CCK2-R), and bombesin receptors. Due to the enormous amount of compounds described, we will focus on target structures where derivatives are already in clinical routine or at least in clinical studies.

5.1. Somatostatin Receptor

Radiolabelled octreotide derivatives are the most well-known and best-established peptide-based radiopharmaceuticals for diagnosis as well as treatment of neuroendocrine tumours (NET) (for an overview, see, e.g., [125]). One of the frequently used tracers for PET is $[^{68}\text{Ga}]\text{Ga-DOTATOC}$ [126], which combines easy accessibility with good targeting properties. Labelling with gallium-68 is possible without an in-house cyclotron using corresponding generators but also limits the daily amount of possible investigations. $[^{68}\text{Ga}]\text{Ga-DOTATOC}$ mainly targets SSTR-2 and, to a lesser extent, SSTR-5. Other radiolabelled PET tracers with comparable clinical accuracy are $[^{68}\text{Ga}]\text{Ga-DOTA-Tyr}^3$-octreotate ($[^{68}\text{Ga}]\text{Ga-DOTATATE};$ mainly SSTR-2 targeting) and $[^{68}\text{Ga}]\text{Ga-DOTA-1-Nal}^3$-octreotide ($[^{68}\text{Ga}]\text{Ga-DOTANOC};$ targeting SSTR-2 and SSTR-5 and, to a lesser extent, also SSTR-3) [8,127–129].

| ![Ga] | AAZTA $^e$ | RT, 10 min | [116] |
| ![Ga] | DFO $^f$ | RT, 5 min | [116] |
| ![Ga] | DOTA $^b$ | 95 °C, 5 min | [116] |
| ![Ga] | DTPA $^g$ | RT, 10 min | [117] |
| ![Ga] | HBED-CC $^h$ | 80–100 °C, 5–20 min | [85] |
| ![Ga] | NODAGA $^i$ | RT, 10 min | [86] |
| ![Ga] | NOTA $^c$ | RT, 10 min | [118] |
| ![Ga] | TRAP/NOPO $^k$ | 95–100 °C, 5 min; RT or 95 °C, 5 min | [87,89] |
| ![Zr] | DFO $^f$ | RT, 30 min | [119] |
| ![Zr] | DOTA $^b$ | 95 °C, 60 min | [97] |
| ![Zr] | FSC $^l$ | RT, 90 min | [120] |
| ![Y] | 3p-C-NTA-NCS $^m$ | CHX-A’’-DTPA $^n$ | RT, 60 min | [106] |
| ![Y] | 3p-C-NTA-NCS $^m$ | DOTA $^b$ | 37–75 °C, 30–60 min | [82] |
| ![Lu] | 3p-C-NTA-NCS $^m$ | AAZTA-5 | RT, 60 min | [106] |
| ![Lu] | 3p-C-NTA-NCS $^m$ | DOTA $^b$ | RT, 10 min | [104] |
| ![Ac] | DOTA $^b$ | RT, 20 min | [121] |
| ![Ac] | Hmacropa $^p$ | RT, within several min | [112] |
| ![Ac] | HEHA $^q$ | 37 °C, 30 min | [122] |

$^a$4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane, $^b$1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, $^c$1,4,7-triazacyclononane-1,4,7-triacetic acid, $^d$1,4,8,11-tetraazacyclododecane-1,4,7,10-tetraacetic acid, $^e$1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, $^f$1,4,7-triazacyclononane-1,4,7-triacetic acid, $^g$1,4,8,11-tetraazacyclododecane-1,4,7,10-tetraacetic acid, $^h$1,4,7-triazacyclononane-1,4,7-triacetic acid, $^i$desferrioxamine B, $^j$diethylenetriamine pentaacetic acid, $^k$N,N’-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N’-diacetic acid, $^l$1,4,7-triazacyclononane-1-glutamic acid-4,7-acetic acid, $^m$1,4,7-triazacyclononane phosphonic acid, $^n$1,4,7-triazacyclononane-1,4-bis[methylene(hydroxymethyl)phosphonic acid]-7-methylene(2-carboxyethyl) phosphonic acid), $^o$fusarinine C, $^p$[4-2-(bis-carboxy-methylamino)-5-(4-isothiocyanatophenyl) pentyl]-7-carboxymethyl[1,4,7] triazanonan-1-yl]acet acid, $^q$2-(p-isothiocyanatobenzyl)-cyclohexylidihydroxyethylamidine pentaacetic acid, $^r$N,N’-bis[6-carboxy-2-pyridylmethyl]-ethylenediamine-N,N’-diacetic acid, $^s$N,N’-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6, $^t$1,4,7,10,13,16-hexaazacycloundecane-N,N,N’,N’,N”,N”-hexaacetic acid.
At present, only ⁶⁸Ga-labelled octreotide derivatives are used in clinical routine with PET but there are approaches to establish also ⁶⁴Cu- and ¹⁸F-labelled analogues [130]. Already in 2001, a first in human study with ⁶⁴CuCu-TETA-octreotide was described [131]. In this trial with two patients, ⁶⁴CuCu-TETA-octreotide demonstrated superior imaging properties compared to OctreoScan® but also showed low in vivo stability. Pfeifer et al. evaluated ⁶⁴CuCu-DOTATATE in a first in human study in 14 NET patients [132]. The images revealed high spatial resolution with good tumour-to-background ratios on early as well as late PET scans. Despite some release of copper-64, in vivo stability of the tracer seemed to be sufficient for imaging purposes. A comparison of ⁶⁴CuCu-DOTATATE and ⁶⁸GaGa-DOTATOC demonstrated that both compounds perform equally but ⁶⁴CuCu-DOTATATE detected significantly more additional true-positive lesions, which was explained by the shorter positron range of copper-64 [133]. Wester et al. [134] developed an ¹⁸F-labelled glycosylated octreotate (Gluc-Lys-[¹⁸F]FP-TOCA) derivative. In a clinical study, this compound was compared with OctreoScan® and demonstrated fast and high tumour uptake with rapid, predominately renal, excretion allowing observation of more than twice as many lesions as with OctreoScan® [135]. The major drawback here was the complex and time-consuming production of the radiopharmaceutical, making a routine use in the clinic very difficult. [¹⁸F]-fluoroethyl triazole [Tyr²]octreotate ([¹⁸F]FET-βAG-TOCA) [136] is another ¹⁸F-labelled octreotide derivative studied in humans. Synthesis is based on click chemistry and is an improvement compared to Gluc-Lys-[¹⁸F]FP-TOCA but the production remains time-consuming and complex (HPLC separation is necessary) with low radiochemical yield compared with ⁶⁸Ga-labeling strategies. However, a first in human study showed rapid blood clearance with good tumour-to-background ratios, similar to ⁶⁸Ga-octreotide derivatives leading to further clinical trials, which are still ongoing [137]. A set of alternative labelling strategies including the introduction of aluminium mono-[¹⁸F]fluoride cations ([¹⁸F]AlF³⁻), labelling of SiFA by ¹⁸F-¹⁸F isotopic exchange reactions (IEX), and 1-step ¹⁸F-¹⁸F IEX on trifluoroborates such as trialkylammoniomethyl-BF₃ are currently being evaluated (for a review, see [138]). Initial clinical trials with ¹⁸F-AlF-NOTA-octreotide [48] and ¹⁸F-SiFAlin-TATE [139] most recently published indicate promising data. Further studies will demonstrate if these compounds might replace the established ⁶⁸Ga-labelled octreotide derivatives.

For a long time, it was a paradigm that internalisation of the radiopharmaceutical is a prerequisite for high tumour accumulation and especially necessary for the endoradiotherapy of tumours. Thus, the focus was on the development of SSTR agonists, which reveal high internalisation. Recently, H-Phe(pNO₂)-cyclo(DCys-Tyr-dTrp-Lys-Thr-Cys)-dTyr-NH₂ (BASS) [140] and H-Cpa-cyclo[DCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys]-dTyr-NH₂ (JR11) [141] have been introduced. Both compounds are antagonists binding exclusively to SSTR-2, which does not internalise. Surprisingly, it could be demonstrated in murine tumour models that the antagonists have a higher tumour accumulation and retention than found for the corresponding agonist. These findings result in the hypothesis that an agonist that triggers a strong internalisation but binds to a limited number of high-affinity receptors might be a less-efficient targeting agent than an antagonist that lacks internalisation capabilities but binds to a larger variety of receptor conformations [140]. In an initial clinical study comparing the antagonist ⁶⁸GaGa-NODAGA-JR11 (also known as ⁶⁸GaGa-OPS202) and the agonist ⁶⁸GaGa-DOTATOC, it was found that the uptake (mean SUV max) in the lesions were comparable but the background, especially in the liver, was much lower for ⁶⁸GaGa-NODAGA-JR11, leading to much higher sensitivity [142] (see also Figure 1).

Octreotide derivatives labelled with yttrium-90 or lutetium-177 are used for the treatment of NETs (PRRT), including ⁶⁹YDOTATOC and ¹⁷⁷LuLu-DOTATATE [143]. In theory, depending on the physical properties of the different isotopes, ⁶⁹YDOTATOC should be used for the treatment of larger lesions and ¹⁷⁷LuLu-DOTATATE for smaller tumours. Nevertheless, in clinical praxis, ¹⁷⁷LuLu-DOTATATE is more frequently used than the ⁶⁹Y-labelled analogue. Most recently, it was suggested that therapy protocols, including a combination of both radiopharmaceuticals, might be of advantage for the treatment of neoadjuvant and metastatic large volume NETs [143].

Studies show that a limitation of the ¹⁷⁷LuLu-DOTATATE therapy is that a large number of patients only achieve stabilisation of disease (26–55%) or are even refractory to β-radiation (18–32%)
[144]. Thus, an alternative therapy strategy involves α-emitting isotopes for the treatment of NET. An initial clinical trial investigated the therapeutic effect of [225Ac]Ac-DOTATATE as an end-line treatment option [144]. A morphological response was assessed in 24/32 patients (15 partial remission; 9 stable disease). There was no documented disease progression or deaths in the median follow-up of 8 months and a significant decrease in the plasma chromogranin level post-therapy.

Meanwhile, SSTR antagonists are not only studied for diagnostic approaches but also for use as therapeutic radiopharmaceuticals. Dalm et al. [145] compared [177Lu]Lu-satoreotide tetraxetan ([177Lu]Lu-DOTA-JR11) and [177Lu]Lu-DOTATATE tracer accumulation in an in vitro cell uptake assay and the therapeutic effect in a murine tumour model and found 5-times higher cell uptake as well as 4.4-times higher tumour radiation dose for the antagonist. As expected for the antagonist, the majority of activity was membrane-bound and for the agonist, internalised. They concluded that SSTR antagonists might enhance PRRT and allow therapy for cancer types with relatively low receptor expression. An initial clinical trial with [177Lu]Lu-DOTA-JR11 indicates that this tracer delivers high radiation doses to the target structure with favourable tumour-to-normal organ dose ratios [146]. The therapeutic outcome is promising and supports that radiolabelled SSTR antagonists might be an alternative treatment strategy for NETs. However, for the antagonist, more severe hepatotoxicity was found during the treatment compared to agonist-based therapies, which might be reduced by modifications of the treatment protocols.

![Figure 1](image)

**Figure 1.** [68Ga]Ga-OPS202 PET/CT [antagonist—(A,B)] and [68Ga]Ga-DOTATOC PET/CT [agonist—(C,D)] images of a patient with ileal neuroendocrine tumours, showing bilobar liver metastases (dashed lines indicate level of transaxial slices). Studies were performed on the same scanner within 2 months and show same gray (maximal-intensity projections, (A,C) and colour scale (transaxial fusion images, (B,D)). Importantly, background activity was lower in liver, intestine, and thyroid with [68Ga]Ga-OPS202 than with [68Ga]Ga-DOTATOC allowing better identification of the lesions in the liver which are confirmed by subsequent MRI. (Adapted from Nicolas et al., originally published in J Nucl Med [142]).

5.2. Prostate-Specific Membrane Antigen
Different studies revealed that the sequence Glu-C(O)-AA, with AA as a variable amino acid, is a potent inhibitor of glutamate carboxypeptidase II (GCPII) (see, e.g., [147]), an enzyme highly expressed on prostate carcinoma cells and also known as PSMA. Based on this finding, a variety of radiolabelled derivatives has been introduced, which have been labelled with different isotopes including iodine-125, technetium-99m, lutetium-177, actinium-225, fluorine-18 and gallium-68 (see, e.g., [85,148–152]). Although when accurately considered, these radiopharmaceuticals are more peptidomimetics than peptides, they were included here because many characteristics including labelling strategies are similar to those found for peptides. Meanwhile, a great diversity of compounds have been described (for a review, see [153]). Here we will focus on compounds studied in patients or already in clinical routine for diagnosis and therapy.

The big success of this class of radiopharmaceuticals is based on Glu-C(O)-Lys(Ahx-[68Ga]Ga-HBED-CC) ([68Ga]-PSMA-11) [85] (Figure 2), which was introduced for prostate carcinoma (PCa) diagnosis in 2011 [154]. The initial clinical study indicated that [68Ga]-PSMA-11-directed PET imaging is significantly superior to alternative methods used for the detection of recurrent PCa [155], which is meanwhile confirmed by a large number of additional reports (for a review, see, e.g., [156,157]). Another [68Ga]-labelled derivative used in clinical diagnostic of prostate cancer is [68Ga]-Ga-PSMA-I&F [158]. In contrast to PSMA-11, the chelator 1,4,7,10-tetraazacyclododecane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) is used for complexation. Due to interaction with an additional arene-binding site within the PSMA structure, aromatic groups are necessary for high-affinity binding [159]. HBED-CC includes already aromatic residues whereas DOTAGA does not, which is why amino acids containing aromatic side chains are included in the spacer moiety to improve binding properties. The comparison of both tracers in patients revealed a higher sensitivity and therefore the slight superiority of [68Ga]-PSMA-11 [160]. Other [68Ga]-labelled compounds studied include [68Ga]-Ga-THP-PSMA [161] and [68Ga]-Ga-P16-093 [162]. Of advantage for [68Ga]-Ga-THP-PSMA might be the rapid production via a kit labelling procedure and the low tracer accumulation in the body. Regardless of that, in an initial study uptake in tumour lesions was lower (as found for [68Ga]-Ga-PSMA-I&F) but for a final concrete result, further studies where comparison of uptakes of both tracers in the same patient have to be carried out. [68Ga]-Ga-P16-093, which differs from [68Ga]-PSMA-11 only by a different linker moiety, demonstrated, in a pilot assessment, equivalent imaging properties in the detection of sites of PCa recurrence. Again, studies that are more comprehensive are needed.

Due to the increasing demand of PSMA/PET investigations, which is hardly satisfied by using [68Ga]-Ga-generators producing short-lived gallium-68, [18F]-labelled compounds with a longer half-life enabling local distribution and lower positron energy, which might increase the resolution, have become a focus of interest. [18F]-labelled PSMA targeting derivatives that are studied in patients include [18F]-DCFBC [163], [18F]-DCFPyL [164], [18F]-PSMA-11 [165], [18F]-PSMA-1007 [152], [18F]-CTT1057 [166], and [18F]-JK-PSMA-7 [167]. The first in-man studies have been carried out with [18F]-DCFBC but these studies demonstrated slow clearance with high background activity [153].

An optimisation step where 4-[18F]fluorobenzyl-L-cysteine was replaced by 6-[18F]fluoronicotinoyl-L-lysine resulted in the more hydrophilic [18F]-DCFPyL with much faster renal elimination [164]. In a direct comparison of [18F]-DCFPyL and [68Ga]-PSMA-11, the [18F]-labelled radiopharmaceutical was found to perform equally well as the [68Ga]-labelled reference [168]. Based on the binding motif of [68Ga]-PSMA-11, [18F]-PSMA-1007 was developed. In contrast to other derivatives, [18F]-PSMA-1007 revealed low activity concentration in ureter and bladder but also higher background in the liver [169]. However, high imaging quality was found with both [18F]-PSMA-1007 and [18F]-DCFPyL, resulting in identical clinical findings in the evaluated routine situations. The low activity in the ureter is of advantage for [18F]-PSMA-1007 in the delineation of local recurrence and the lower liver uptake of [18F]-DCFPyL in cases where liver metastases occur [170]. Contrary to other PSMA targeting compounds, which are areua-based, [18F]-CTT1057 is a phosphoramidate-based PSMA inhibitor. This compound resulted from a series of derivatives which differ in the linker between binding sequence and 4-[18F]fluorobenzoyl group [171]. A preliminary study with patients showed a low radiation burden as well as similar distribution as found for areua-based analogues like [18F]-DCFPyL [166]. Efforts are made to optimise pharmacokinetics and detection rates of [18F]-DCFPyL.
in patients with very low PSA levels. Therefore, different prosthetic groups were conjugated [167]. Out of this set, \(^{18}F\)F-JK-PSMA-7 performed best and was further evaluated in patients. In this clinical setting, \(^{18}F\)F-JK-PSMA-7 showed no drug-related adverse effects but also revealed no inferior sensitivity in detecting prostate cancer lesions, compared to \(^{68}Ga\)-PSMA-11 [172]. In a few selected patients, \(^{18}F\)F-JK-PSMA-7 revealed superior sensitivity compared to the lead structure \(^{18}F\)F-DCFPyL in detecting PSMA-positive lesions in small lymph nodes. Another approach is based on the use of \(^{18}F\)AlF for labelling of PSMA-11. An automated labelling process has been validated [173] and an initial clinical study to evaluate the safety of administration and radiation dosimetry has been performed [174]. Here, \(^{18}F\)F-PSMA-11 could be safely administered with a mean effective dose comparable with \(^{18}F\)F-DCFPyL. The ability to detect PSMA-positive lesions and the performance compared to other PSMA-targeting tracer needs to be further explored.

Based on the successful introduction of the diagnostic radiopharmaceuticals, derivatives allowing endoradiotherapy have also been developed. Because HBED-CC is not optimal for the complexation with therapeutically used \(\alpha\)- and \(\beta\)-emitter like actinium-225 and lutetium-177, this moiety had to be replaced. As chelator of choice DOTA and its derivatives have been introduced. As indicated for high binding affinity and receptor internalisation, aromatic moieties interacting with the arene-binding pocket would be of advantage; thus, spacers containing aromatic groups are included. The most used \(\beta\)-emitting radiopharmaceuticals are \(^{177}Lu\)Lu-PSMA-617 [151] and \(^{177}Lu\)Lu-PSMA-I&T [158]. A retrospective multicentric clinical trial including more than 140 patients demonstrated the favourable safety and efficacy of \(^{177}Lu\)Lu-PSMA-617 therapies [175]. Additional prospective clinical trials are ongoing [e.g., TheraP (NCT03392428) and VISION (NCT03511664)] to evaluate the potential of this endoradiotherapy, especially with regard to improved patient survival. Another study including 100 patients treated with \(^{177}Lu\)Lu-PSMA-I&T showed that this tracer is also well-tolerated and demonstrated good treatment response in a subgroup of patients [176]. It was also observed that treatment outcome was worse in patients with organ metastases and elevated lactate dehydrogenase in blood tests. In the most recent approaches, albumin binders are suggested for endoradiotherapy to modify pharmacokinetics and to enhance therapeutic efficacy [177]. Evans blue (EB) is one compound used for this purpose; thus, \(^{177}Lu\)Lu-EB-PSMA-617 has been introduced [178], which revealed in a first in human study [179] higher accumulation in metastatic castration-resistant prostate cancer (mCRPC) than \(^{177}Lu\)Lu-PSMA-617 and that a lower dose of the new radiopharmaceutical appears to be already effective in treating tumours. The elevated uptake of \(^{177}Lu\)Lu-EB-PSMA-617 in kidneys and red bone marrow seems to be well tolerated despite that studies which are more comprehensive are necessary to assess the potential of this approach.

As discussed, \(^{177}Lu\)-labelled PSMA enzyme inhibitors like \(^{177}Lu\)Lu-PSMA-617 and \(^{177}Lu\)Lu-PSMA I&T have favourable dosimetry and convincing therapeutic response but approximately one-third of patients were found to respond only for a short period or were non-responders. Moreover, problematic is that dose escalation is limited by chronic haematological toxicity [180]. Based on these limitations, \(\alpha\)-emitting radiopharmaceuticals have been introduced. The isotopes included are astatine-211, bismuth-213, and actinium-225, but so far only PSMA-617 labelled with bismuth-213 or actinium-225 were studied in clinical trials. In a case report, a patient who was progressive under conventional therapy showed remarkable response 11 months after two cycles of \(^{212}Bi\)Bi-PSMA-617 [181]. The \(\alpha\)-emitting \(^{212}Ac\)Ac-PSMA-617 appeared to have high clinical efficacy when compared to \(\beta\)-emitting therapy with \(^{177}Lu\)Lu-PSMA-617 [182]. However, \(\alpha\)-emitting therapy resulted in a higher radiation dose for the salivary glands, which is why the authors suggest modifications of the treatment regimen to overcome this problem.
5.3. Integrins

Already some decades ago, great hope has been pinned on the “starvation” of tumours by inhibition of tumour-induced angiogenesis. One target structure involved in these processes is the integrin αβ3; thus, a great variety of radiopharmaceuticals have been developed to target this receptor to allow treatment planning and control of corresponding antiangiogenic therapies (for a review, see, e.g., [4,184,185]). Most of these peptides are based on the cyclic pentapeptide structure c(RGDfV) developed by Kessler’s group in 1991 [186]. Already, the initial compounds labelled with iodine-125 demonstrated receptor specific tumour accumulation [187]. In subsequent investigations, optimisations improving pharmacokinetics, tracer uptake, and target retention were performed, resulting in a comprehensive set of radiopharmaceuticals of which several have been studied in patients. The first and most intensive evaluated compound in humans has been [18F]F-Galacto-RGD [11,188]. The initial clinical trial demonstrated receptor-specific accumulation in integrin αβ3 positive tissue and rapid renal elimination with low background activity in most tissue [189]. Further studies confirmed these findings and revealed that the radiopharmaceutical is well tolerated with an effective dose comparable with an [18F]FDG-PET scan [190–192]. Based on these results, alternative [18F]-labelled compounds have been examined in clinical trials including [18F]F-RGD-5K, [18F]F-Fluciclatide, [18F]FP-PRGD2, [18F]F-Alfatide, and [18F]F-Alfatide II. [18F]F-RGD-5K is also based on c(RGDfK) conjugated to a sugar moiety but labelling is done via click chemistry, reducing the production time to 70 min [193]. For the synthesis of [18F]F-Fluciclatide, a disulfide bridged peptide structure, resulting from a phage display library and demonstrating higher binding affinity for αβ3 as for αβ5, is used [194]. Labelling was carried out via oxime formation but did not reduce production time dramatically compared to [18F]FGalacto-RGD. Initially, Wester’s group demonstrated that combining more than
one RGD binding epitope in one molecule improved binding affinity [31,195]. This multimerisation approach was applied for $[^{18}F]$F-PPRGD2 [196] as well as for $[^{18}F]$F-Alfatide [197] and $[^{18}F]$F-Alfatide II [46], which contain two binding epitopes. Labelling of FPPRGD2 was carried out via $[^{18}F]$-fluoropropionic acid as a prosthetic group. Alfatide and Alfatide II, which differ in the design of the spacer/branching unit, making the latter more stable, were labelled using $[^{18}F]$aluminium fluoride. With exception of the $[^{18}F]$aluminium fluoride labelled derivatives, all other $[^{18}F]$-labelled compounds are characterised by complex synthesis routes including at least one HPLC separation step. To overcome this drawback, $[^{68}Ga]$-labelled alternatives have been suggested. Three of these derivatives, namely $[^{68}Ga]$Ga-NOTA-RGD [118], $[^{68}Ga]$Ga-NODAGA-RGD [86], and $[^{68}Ga]$Ga-NOTA-PRGD2, [197] were tested in clinical trials (examples of PET images of the different RGD-based tracers in clinical studies are presented in Figure 3).

Although the structure and label of the clinically studied RGD-tracers differ, the in vivo pharmacokinetic properties are comparable with predominant renal elimination and prominent uptake in kidneys and bladder. Thus, initial voiding is recommended before starting the PET/CT scan. Additional increased activity concentration was found in the liver, spleen, and intestines, which is why optimal regions for lesion detection are suggested to be lungs, mediastinum, head-and-neck area, thorax including the breast, skeletal system and the extremities [5,184]. Because the RGD-peptides do not cross the intact blood–brain-barrier, background in brain is very low, allowing easy identification of brain tumours even if tumour uptake is low (see, e.g., [198]). Identification of lesions in the body differs inter- as well as intra-individual [190]. A great diversity of different tumour entities including melanoma, sarcoma, glioblastoma, non-small cell lung cancer, breast cancer, rectal cancer, bone metastasis, and renal cell cancer (for a review, see [184]) have been studied. Due to differences in the imaging protocols and low patient numbers, final conclusions are difficult to draw. However, sensitivity in lesion detection was over 90% for sarcoma, non-small cell lung cancer, glioblastoma, renal cell cancer, breast cancer, and some bone metastases. Moreover, where immunohistochemical staining of corresponding tumour tissue was possible, a correlation with receptor expression was found [191].

A variety of preclinical studies have demonstrated the potential to monitor response to antiangiogenesis therapies in murine tumour models [199–203]. All studies, using different antiangiogenic pharmaceuticals including Endostar, sunitinib, ZD4190, linifanib, and dasatinib, already showed a reduction of uptake within 3 days after treatment start, where tumour size was only slightly affected and $[^{18}F]$FDG did not reveal significant changes in uptake. Translation into clinics is rather difficult and only a few clinical studies have been published. A pilot study comparing therapy control of a bevacizumab-containing therapy using $[^{18}F]$F-PPPRGD2 or $[^{18}F]$FDG, respectively, showed a decrease of tumour uptake of $[^{18}F]$F-PPPRGD2 early after therapy start [204]. Another clinical trial included 38 patients with solid malignancies and studied the predictive value of $[^{18}F]$F-Alfatide before an antiangiogenic therapy with apatinib was started [205]. It was demonstrated that lesions with higher tracer uptake showed better response to the apatinib therapy. These initial data are promising but more comprehensive studies that clearly demonstrate that the therapeutic effects of anti-angiogenic therapies can be predicted and controlled are necessary for the successful translation of this tracer into clinical routine.

It has to be mentioned that not only radiopharmaceuticals targeting the integrin $\alpha_5\beta_3/\alpha_\text{v}\beta_3$ are developed but also compounds targeting other integrins including $\alpha_\text{v}\beta_5$ and $\alpha_\text{v}\beta_1$ (for a review, see, e.g., [4,206]). Until now, to our knowledge, none of these compounds have entered clinical trials and will not be discussed here.
5.4. Chemokine Receptor

The chemokine receptor-4 CXCR4 and its ligand CXCL12 play an important role in tumour development and metastasis and are found in breast, prostate, lung, colorectal and brain tumours (for a review, see, e.g., [211]). This receptor mediates organ-specific metastasis and the level of expression was found to be predictive for the metastatic potential of the tumours [212]. Due to the central role in tumour development, a variety of inhibitors of the CXCR4/CXCL12 interaction has been developed during the last decade [213,214]. Based on these compounds, radiolabelled analogues for non-invasive determination of the CXCR4 expression have been evaluated [211]. They are based either on the bicyclams AMD3100 and AMD3465, on the disulfide-bridged peptide T-140, or on the cyclic pentapeptide FC-131. So far, only [68Ga]Ga-NOTA-NFB and [68Ga]Ga-Pentixafor have been included in clinical studies. [68Ga]Ga-NOTA-NFB was studied in healthy volunteers and a limited number of glioma patients [215]. The compound was well tolerated with highest activity accumulation found in the liver, spleen, kidneys, and bladder. The low background in the brain and the receptor specific accumulation in the tumour suggest further investigations to confirm the potential of diagnosing and evaluating glioma patients. More extensive clinical studies have been carried out with [68Ga]Ga-Pentixafor (Figure 4) (for an overview, see, e.g., [211]). However, accumulation in solid cancer and metastases seems not as high as expected from in vitro CXCR4 expression profiles [216]. Thus, the detectability of solid cancer using [68Ga]Ga-Pentixafor seems to be inferior, as found for [18F]FDG. This is confirmed by a most recent study, which concludes that “CXCR4-directed imaging may not play a major role in the management of solid tumours in the majority of patients” [217]. In contrast, studies including hematologic malignancies where high CXCR4 expression is found, like non-Hodgkin-lymphoma, multiple myeloma, chronic lymphocytic leukaemia and acute myeloid leukaemia, depict the potential of [68Ga]Ga-Pentixafor PET/CT as a diagnostic marker for these malignancies [211]. [68Ga]Ga-Pentixafor for PET/CT was able to image
disease manifestation in 10/14 patients with myeloid leukaemia [218] and in 23/34 patients in another study [219]. Further evaluations showed the applicability of [68Ga]Ga-Pentixafor PET/CT to identify patients with CXCR4-positive acute myeloid leukaemia [220] and chronic lymphocytic leukaemia [221]. It is assumed that CXCR4-directed imaging might be more included in patient selection for corresponding therapeutic approaches rather than to evaluate disease extent.

In another approach, Pentixafor was modified allowing the use for endoradiotherapy with lutetium-177 and yttrium-90. The resulting [177Lu]Lu/[90Y]Y-Pentixather [222] was studied in patients with advanced stage multiple myeloma [223], diffuse large B cell lymphoma [224], and acute myeloid leukaemia [225]. Initial data are promising, but extended studies are needed to evaluate the potential of this new treatment option.

![Figure 4. Structure of [68Ga]Ga-Pentixafor and PET MIP of a patient with multiple myeloma (modified from Wester et al., originally published in Theraonstics [226]).](image)

5.5. Other Target Structures Expressed on Tumour Cells

Beside the above-mentioned radiopharmaceuticals and their corresponding target structures, a variety of other radiolabelled compounds are used for the non-invasive determination of a set of receptors overexpressed on tumour cells. These include CCK2-R, the gastrin-releasing peptide receptors (GRP-R), the uPAR, the glucagon-like peptide receptor 1 (GLP-1), melanocortin 1 receptor, neurotensin receptor, neurokinin 1 receptor (NK1-R), neuropeptide Y receptor (NPY-R), the vasoactive intestinal peptide receptors (VPAC1 and 2), and caspase-3 (for an overview, see, e.g., [123,124]). To our knowledge, only radiopharmaceuticals targeting CCK2-R, GRP-R, uPAR, GLP-1, NK1-R, VPAC1, and caspase-3 are investigated in patients so far. Due to the great diversity of different compounds and to not go beyond the scope of this review, we will give only a brief summary here.

A great variety of NK1 targeting radiopharmaceuticals has been developed and studied in initial clinical trials (for a review, see [227]). However, PET tracer development strongly focused on the diagnosis of central nervous system related diseases and mainly uses small molecule antagonists of the receptor as lead structures. Diagnostic tracers in oncology are mainly described for SPECT applications and are derivatives of substance P. Moreover, there are different compounds labelled with bismuth-213, actinium-225, lutetium-177 and yttrium-90 for tumour treatment with the major focus on local administration to cure glioblastoma (see, e.g., [228]).

The value of radioiodinated VIP for peptide receptor scintigraphy of carcinoid patients was already explored in the 1990s [229]. Because VPAC1 is highly expressed on prostate cancer cells more recently, 25 patients undergoing radical prostatectomy were imaged with PET/CT preoperatively with [64Cu]Cu-TP3805, and the tracer allowed delineation of prostate carcinoma and is worthy of further studies [230]. Similar findings are described for patients with breast cancer [231].
Most attempts to image CCK2-R expression are based on minigastrin derivatives labelled with indium-111 or technetium-99 m for SPECT (for a review, see [232]). Up to now, only one patient was investigated with \(^{68}\text{Ga}\)Ga-DOTA-MG0 for PET imaging, revealing increased uptake in the right thyroid with physiological uptake in the stomach, together with highly reduced uptake in the liver, spleen and kidneys compared to \(^{68}\text{Ga}\)Ga-DOTA-TATE[233]. Already in 2002, \(^{68}\text{Y}\)Y-DTPA-MG0 was studied in 8 patients [234] with limited therapeutic success and severe nephrotoxic side effects, a reason why this study was not continued. Recently, pharmacokinetic properties, dosimetry, and the targeting ability of \(^{177}\text{Lu}\)Lu-DOTA-PF11N was tested in an initial clinical study for potential use of CCK2 receptor-based endoradiotherapy [235]. Tumour uptake seems sufficient for successful therapeutic use, with the stomach as the main dose-limiting organ.

Caspase-3 is a cysteine protease playing a central role during apoptosis [236] and is of interest as a target structure to monitor therapies aimed to activate the apoptotic pathway [124]. The \(^{19}\text{F}\)F-labelled pentapeptide CP-18 is a substrate of caspase-3, which showed increased activity uptake in apoptotic thymi in mice [237]. Based on these promising findings, \(^{19}\text{F}\)F-CP-18 was studied in seven healthy volunteers [238]. The images showed uptake in the liver, heart, testes, kidneys, and bladder and due to the predominantly renal excretion, the critical organ in terms of dosimetry was the bladder wall.

The GRP-R family consists of four receptors (BBR1-4) of whom three are expressed in humans. Especially, BBR1 and BBR2 are upregulated in cancer cells, including breast, colon, lung, pancreatic, and prostate cancers [239]. An initial lead structure for tracer development was found in the 14 amino acids containing bombesin (BBN) [240]. Corresponding compounds revealed low stability in humans; thus, further development was focused on the C-terminal sequence containing amino acid 7 to 14 of BBN and introduced a variety of sequence modifications to improve the metabolic stability (see review [124]). One of the first PET tracers in clinical studies was \(^{68}\text{Ga}\)Ga-DOTA-PEG5-[DTyr\(^\beta\)-Ala\(^{11}\),Thi\(^{13}\),Nle\(^{14}\)]BBN(6-14) amide ((\(^{68}\text{Ga}\)Ga-BZH3). It was mainly investigated in patients with glioma, where it showed superior tumour grading in comparison to \(^{18}\text{F}\)FDG [241]. Another peptide that entered clinical trials is DO3A-CH\(_2\)CO-G4-aminobenzyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH\(_2\) (AMBA), which was initially labelled with lutetium-177 and subsequently with gallium-68 [124]. However, detailed data concerning these studies are not yet available. As already discussed for SSTR targeting, radiopharmaceuticals antagonists are becoming more popular and have also been developed to target GRP-R with superior properties and reduced side effects. An initial clinical study using \(^{68}\text{Ga}\)Ga-DOTA-PEG4-trh-DPhe-Glu-Trp-Ala-Val-Gly-His-Sta-Leu-NH\(_2\) \((\text{r}^{68}\text{Ga}\text{Cu}-\text{CB-TE2A-AR06)}\) in prostate cancer patients showed favourable biodistribution with low activity concentration in kidneys and intestine but high tumour uptake [242]. Another BBN antagonist was developed by Maina et al. [243] and studied in prostate and breast cancer patients. Uptake of \(^{68}\text{Ga}\)Ga-SB3 was found in approximately 50% of the studied patients. Further tracers studied in patients were NeoBomb1 and \(^{68}\text{Ga}\)Ga-BAY86-7548/\(^{68}\text{Ga}\)Ga-RM2. First in-man studies with \(^{68}\text{Ga}\)Ga-NeoBomb1 in prostate cancer patients showed that the compound is well tolerated and that primary, as well as multimetastatic foci, could be detected [6]. Additional evaluations are ongoing to demonstrate the potential of the tracer. \(^{68}\text{Ga}\)Ga-BAY86-7548/\(^{68}\text{Ga}\)Ga-RM2 was also studied in prostate cancer patients [244] but also included breast cancer patients [245] in a subsequent study. Moreover, the tracer was compared in a head-to-head study with \(^{68}\text{Ga}\)PSMA-11 in patients with biochemically recurring prostate cancer [246]. In this study, \(^{68}\text{Ga}\)PSMA-11 performed superior to \(^{68}\text{Ga}\)Ga-BAY86-7548/\(^{68}\text{Ga}\)Ga-RM2, but findings showed similar uptake between the two tracers in suspected lesions.

The uPAR is a membrane-anchored receptor for the corresponding plasminogen activator. This serine protease is activated if bound to the receptor and cleaves plasminogen to plasin that activates proteolytic processes on the extracellular matrix [247]. Due to the overexpression on breast, prostate, pancreatic, and colorectal cancer, where it was found to correlate with tumour aggressiveness, it has become an attractive target structure for the development of PET tracers [124]. One compound studied in patients with breast, prostate, and bladder cancers is \(^{64}\text{Cu}\)Cu-DOTA-AEI05 [248] which was well tolerated and showed rapid renal elimination. Despite low plasma half-life, primary
tumours in breast and prostate cancer patients could be detected. Subsequently, the chelator DOTA was replaced by NOTA and \(^{68}\text{Ga}\)Cu-NOTA-AE105 was studied in patients with the same tumour entities where comparable results as for the initial compound were found [249].

The GLP-1 receptor is expressed on beta cells and is an ideal target structure for the non-invasive determination of the beta-cell mass [124]. The receptor is involved in the regulation of the balance between glucose and insulin levels but is also expressed on insulinoma [250]. The endogenous glucagon-like peptide 1 has a very short half-life and can hardly be used for imaging [251]. Exendin-4, isolated from the saliva of the Gila monster Heloderma suspectum, also binds to this receptor and demonstrated higher stability [252]. Thus, [Nle\(^{14}\text{Lys}\(^{40}\text{Ahx-DOTA-}\(^{68}\text{Ga}\)-NH\(_2\)]exendin-4 ([\(^{68}\text{Ga}\)]Ga-DOTA-exendin-4) was developed and compared with the \(^{111}\text{In}\)-labelled analogue in five patients with insulinoma. The study revealed that the tracer allows the delineation of tumour foci with a higher tumour/background ratio for the \(^{68}\text{Ga}\)-labelled derivative [253]. The superiority of \(^{68}\text{Ga}\)-DOTA-exendin-4 is confirmed by a more comprehensive trial including 52 patients [254]. \(^{68}\text{Ga}\)Ga-NOTA-MAL-Cys40-exendin-4 ([\(^{68}\text{Ga}\)]Ga-NOTA-exendin-4) is another compound studied in patients with insulinomas [255]. The \(^{68}\text{Ga}\)Ga-NOTA-exendin-4 PET/CT showed a sensitivity of 97.7\%, which is significantly higher than for commonly used imaging strategies. Most recently, dosimetry calculations for \(^{68}\text{Ga}\)Ga-NODAGA-exendin-4 have been presented, indicating low radiation burden of the corresponding PET/CT investigations [256].

Recently, fibroblast activation protein inhibitors (FAPI) have become a focus of interest because this transmembrane serine protease is involved in the development of a great variety of tumour types [257] and initial clinical studies have demonstrated very promising results with high tumour uptake and good tumour/background ratios [258]. Most of the studied \(^{68}\text{Ga}\)-labelled radiopharmaceuticals are based on a Gly-Pro unit, which is found to be a binding motive of this protease. However, these quinolone-based compounds [259] are seen more as small organic molecules and are not in the scope of this review.

6. Summary and Conclusions

Due to the central role of peptide/receptor interactions, the development of radiolabelled probes for the use in nuclear medicine tracer techniques has been of interest for several decades. Besides the broad applicability, the high diversity of labelling options and approaches to optimise the pharmacokinetic properties makes this class of tracer attractive for the development of radiopharmaceuticals for diagnosis and therapy of oncolgical diseases. As described above, even the problematic low metabolic stability of a variety of lead compounds can be overcome by various ways of modifications. This led to the development of radiopharmaceuticals for a diversity of target structures including SSTR, integrins, PSMA, chemokine receptor-4, CCK2-R, GRP-R, uPAR, and GLP-1. Radiopharmaceuticals binding to SSTR and PSMA are already in clinical routine for the diagnosis and treatment of neuroendocrine tumours and prostate cancer, respectively. Others are being studied in clinical trials and their outcomes have to demonstrate their potential.

For PET diagnosis, gallium-68 was the best choice of isotope, but due to the limited activity provided from corresponding generators, there has been a renaissance in the development of \(^{18}\text{F}\)-labelled analogues. Despite the improvement of the accessibility of corresponding prosthetic groups especially for remote controlled production processes, further developments might be needed. An alternative labelling strategy introduces \(^{18}\text{F}\)-aluminium fluoride, which allows straightforward labelling involving chelator systems in analogy to radiometals. However, the potential of this strategy has not yet been demonstrated in routine clinical use. For labelling of proteins and antibodies, zirconium-89 has come into focus because its longer half-life fits better to the elimination kinetics of these molecules. For small peptides, this might be of no great benefit. In PRRT, the \(\beta\)-emitters yttrium-90 and lutetium-177 are the isotopes mainly used. Recently, \(\alpha\)-emitting isotopes like astatine-211 and actinium-225 were also investigated and demonstrated in initial studies some positive results compared to therapies with \(\beta\)-emitters.

For a long time, it was thought that internalising agonists are superior to non-internalising antagonists, but recent studies with radiolabelled antagonists of SSTR-2 revealed contrary results and
initiated a paradigm shift. Meanwhile, first antagonists for diagnosis and therapy of NET are investigated in clinical trials, and for other receptors like the GRP-R, antagonists are under development.

Altogether, peptide-based radiopharmaceuticals are important tools in molecular imaging using PET as well as theranostics. Besides the established tracer for the diagnosis and therapy of NET and PCa, several others are currently being evaluated and some of them might soon be used in clinical routine (Table 3). Moreover, due to the comprehensive research in developing new labelling strategies as well as in the optimisation of corresponding peptides, the development of peptide-based tracers will remain a central field in radiopharmaceutical research.

Table 3. Peptides used in clinical trials or clinical routine PET diagnosis.

| Peptide/Chelator       | Isotope       | Target Receptor | Tumour Types   | Reference |
|------------------------|---------------|-----------------|----------------|-----------|
| AIF-NOTA-octreotide    | $[^{18}F]$    | SSTR $^a$       | NET $^b$       | [48]      |
| DOTA-JR11 (OPS201)     | $[^{177}Lu]$  | SSTR $^a$ (antagonist) | NET $^b$       | [145]  |
| DOTANOC                | $[^{68}Ga]$   | SSTR-2/3/5 $^a$ | NET $^b$       | [127]    |
| DOTATATE               | $[^{68}Ga]$/$[^{177}Lu]$/[^{90}Y]$/$[^{64}Cu]$/$[^{225}Ac]$ | SSTR-2 $^a$ | NET $^b$       | [125]  |
| DOTATOC                | $[^{68}Ga]$/$[^{90}Y]$ | SSTR-2/5 $^a$ | NET $^b$       | [1]      |
| FET-βAG-TOCA           | $[^{18}F]$    | SSTR $^a$       | NET $^b$       | [143]  |
| Gluc-Lys-[^{18}F]FP-TOCA | $[^{18}F]$    | SSTR $^a$       | NET $^b$       | [134]  |
| NODAGA-JR11 (OPS202)   | $[^{68}Ga]$   | SSTR-2 $^a$ (antagonist) | NET $^b$       | [142]  |
| SiFa/lin-TATE          | $[^{18}F]$    | SSTR $^a$       | NET $^b$       | [139]  |
| TETA-octreotide        | $[^{64}Cu]$   | SSTR-2 $^a$     | NET $^b$       | [131]  |
| CTT1057                | $[^{18}F]$    | PSMA $^c$       | prostate cancer | [166]  |
| DCFPyL                 | $[^{18}F]$    | PSMA $^c$       | prostate cancer | [164]  |
| EB-PSMA-617            | $[^{177}Lu}$  | PSMA $^c$       | prostate cancer | [178]  |
| HBED-CC-PSMA (PSMA 11) | $[^{68}Ga]$/$[^{18}F]$ | PSMA $^c$ | prostate cancer | [85]  |
| JK-PSMA-7              | $[^{18}F]$    | PSMA $^c$       | prostate cancer | [167]  |
| PSMA-I&I               | $[^{68}Ga]$/$[^{177}Lu]$ | PSMA $^c$ | prostate cancer | [158]  |
| PSMA 617               | $[^{177}Lu]$/[^{213Bi}]$/$[^{225}Ac]$ | PSMA $^c$ | prostate cancer | [151]  |
| P16-093                | $[^{68}Ga]$   | PSMA $^c$       | prostate cancer | [162]  |
| PSMA-1007              | $[^{18}F]$    | PSMA $^c$       | prostate cancer | [152]  |
| THP-PSMA               | $[^{68}Ga]$   | PSMA $^c$       | prostate cancer | [161]  |
| Alfatide               | $[^{18}F]$    | integrin α-β5   | tumour angiogenesis | [197]  |
| Alfatide II            | $[^{18}F]$    | integrin α-β5   | tumour angiogenesis | [48]  |
| Fluciclatide           | $[^{18}F]$    | integrin α-β5   | tumour angiogenesis | [194]  |
| FPPRGD2                | $[^{18}F]$    | integrin α-β5   | tumour angiogenesis | [196]  |
| Galacto-RGD            | $[^{18}F]$    | integrin α-β5   | tumour angiogenesis | [11,188]  |
| NODAGA-RGD            | $[^{68}Ga]$   | integrin α-β5   | tumour angiogenesis | [5]  |
The Conflicts Funding:

1. References

Pharmaceuticals 2020, 13, 22

| NOTA-RGD | [68Ga] | integrin $\alpha_{5}\beta_{3}$ | tumour angiogenesis | [118] |
|----------|--------|-------------------------------|-------------------|-------|
| NOTA-PRGD2 | [68Ga] | integrin $\alpha_{5}\beta_{3}$ | tumour angiogenesis | [197] |
| RGD-5K | [18F] | integrin $\alpha_{5}\beta_{3}$ | tumour angiogenesis | [193] |
| NOTA-NFB | [68Ga] | chemokine receptor-4 | glioblastoma | [215] |
| Pentixafor | [68Ga] | chemokine receptor-4 | glioblastoma | [211] |
| Pentixather | [177Lu][90Y] | chemokine receptor-4 | multiple myeloma, diffuse large B cell lymphoma, acute myeloid leukemia | [222] |
| TP3805 | [64Cu] | VPAC1 $^d$ | prostate cancer | [230] |
| DOTA-MG0 | [68Ga] | CCK2-R $^e$ | MTC $^f$ | [233] |
| DTPA-MG0 | [90Y] | CCK2-R $^e$ | MTC $^f$ | [234] |
| DOTA-PP-F11N | [177Lu] | CCK2-R $^e$ | MTC $^f$ | [235] |
| CP-18 | [18F] | caspases | apoptosis | [237,238] |
| CB-TE2A-AR06 | [68Ga] | bombesin | prostate cancer | [242] |
| BAY86-7548/RM2 | [68Ga] | bombesin | prostate/breast cancer | [244,245] |
| BZH3 | [68Ga] | bombesin | glioma | [241] |
| SB3 | [68Ga] | bombesin | prostate/breast cancer | [243] |
| DOTA-AE105 | [64Cu] | uPAR $^g$ | breast, prostate, bladder cancer | [248] |
| NOTA-AE105 | [68Ga] | uPAR $^g$ | breast, prostate, bladder cancer | [249] |
| DOTA-exendin-4 | [68Ga] | GLP-1 $^h$ | insulinoma | [253] |
| NOTA-exendin-4 | [68Ga] | GLP-1 $^h$ | insulinoma | [255] |
| NODAGA-exendin-4 | [68Ga] | GLP-1 $^h$ | Hyperinsulinemic, hypoglycemia | [256] |

$^a$ somatostatin subtype 2 receptor, $^b$ neuroendocrine tumours, $^c$ prostate-specific membrane antigen, $^d$ vasoactive intestinal peptide receptor, $^e$ cholecystokinin receptor 2, $^f$ medullary thyroid carcinoma, $^g$ urokinase-type plasminogen activator receptor, $^h$ glucagon-like peptide receptor 1.

**Funding:** This research received no external funding.

**Conflicts of Interest:** Page: 23

The authors declare no conflict of interest.

**References**

1. De Jong, M.; Bakker, W.H.; Krenning, E.P.; Breeman, W.A.; van der Pluijm, M.E.; Bernard, B.F.; Visser, T.J.; Jermann, E.; Behe, M.; Powell, P.; et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA-d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. *Eur. J. Nucl. Med.* 1997, 24, 368–371.

2. Henze, M.; Schuhmacher, J.; Hipp, P.; Kowalski, J.; Becker, D.W.; Doll, J.; Macke, H.R.; Hofmann, M.; Debus, J.; Haberkorn, U. PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. *J. Nucl. Med.* 2001, 42, 1053–1056.

3. Haubner, R.; Decristoforo, C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. *Front. Biosci.* 2009, 14, 872–886.

4. Haubner, R.; Maschauer, S.; Prante, O. PET radiopharmaceuticals for imaging integrin expression: Tracers in clinical studies and recent developments. *BioMed Res. Int.* 2014, 2014, 871609.

5. Haubner, R.; Finkenstedt, A.; Stegmayr, A.; Rangger, C.; Decristoforo, C.; Zoller, H.; Virgolini, I.J. [68Ga]NODAGA-RGD—Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. *Eur. J. Nucl. Med. Mol. Imaging* 2016, 43, 2005–2013.
6. Nock, B.A.; Kaloudi, A.; Lymperis, E.; Giarika, A.; Kulkarni, H.R.; Klette, I.; Singh, A.; Krenning, E.P.; de Jong, M.; Maina, T.; et al. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeOBOMB1: Preclinical and First Clinical Results. J. Nucl. Med. 2017, 58, 75–80.

7. Valverde, I.E.; Vomstein, S.; Mindt, T.L. Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting. J. Med. Chem. 2016, 59, 3867–3877.

8. Froidevaux, S.; Eberle, A.N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002, 66, 161–183.

9. Murza, A.; Parent, A.; Besserer-Offroy, E.; Tremblay, H.; Karadereye, F.; Beaudet, N.; Leduc, R.; Sarret, P.; Marsault, E. Elucidation of the structure-activity relationships of aepelin: Influence of unnatural amino acids on binding, signaling, and plasma stability. Chem. Med. Chem. 2012, 7, 318–325.

10. Klingler, M.; Decristoforo, C.; Rangger, C.; Sumner, D.; Foster, J.; Sosabowski, J.K.; von Guggenberg, E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics 2018, 8, 2896–2908.

11. Haubner, R.; Kuhnast, B.; Mang, C.; Weber, W.A.; Kessler, H.; Wester, H.J.; Schwaiger, M. [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug. Chem. 2004, 15, 61–69.

12. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αβ3 Integrin for a New Cancer Therapy. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374–1389.

13. Nicole, P.; Lins, L.; Rouyer-Fessard, C.; Drouot, C.; Fulcrand, P.; Thomas, A.; Couvineau, A.; Martinez, J.; Brasseur, R.; Laburthe, M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 2000, 275, 24003–24012.

14. Vagner, J.; Qu, H.; Hruby, V.J. Peptidomimetics, a synthetic tool of drug discovery. Curr. Opin. Chem. Biol. 2008, 12, 292–296.

15. Garcia-Garayoa, E.; Blauenstein, P.; Blanc, A.; Maes, V.; Tourwe, D.; Schubiger, P.A. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 37–47.

16. Becaud, J.; Mu, L.; Karramkam, M.; Schubiger, P.A.; Ametamey, S.M.; Graham, K.; Stellfeld, T.; Lehmann, L.; Borkowski, S.; Berndorff, D.; et al. Direct one-step 18F-labeling of peptides via nucleophilic aromatic substitution. Bioconjug. Chem. 2009, 20, 2254–2261.

17. Okarvi, S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur. J. Nucl. Med. 2001, 28, 929–938.

18. Wester, H.J.; Schottelius, M. (2007) Fluorine-18 Labeling of Peptides and Proteins. In: Schubiger P.A., Lehmann L., Friebe M. (eds) PET Chemistry. Ernst Schering Research Foundation Workshop, vol 64. Springer, Berlin, Heidelberg; pp. 79–111. doi:10.1007/978-3-540-49527-7_4.

19. Vaidyanathan, G.; Zalutsky, M.R. Improved synthesis of N-succinimidyl 4-[[18]F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. Bioconjug. Chem. 1994, 5, 352–356.

20. Schirrmacher, R.; Wangler, B.; Bailey, J.; Bernard-Gauthier, V.; Schirrmacher, E.; Wangler, C. Small Prosthetic Groups in 18F-Radiochrome: Useful Auxiliaries for the Design of 18F-PET Tracers. Semin. Nucl. Med. 2017, 47, 474–492.

21. Wust, F.; Huiltsch, C.; Bergmann, R.; Johannsen, B.; Henle, T. Radiolabelling of isopeptide N epsilon-(gamma-glutamyl)-L-lysine by conjugation with N-succinimidyl-4-[[18]F]fluorobenzoate. Appl. Radiat. Isot. 2003, 59, 43–48.

22. Lang, L.; Eckelman, W.C. One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl. Radiat. Isot. 1994, 45, 1155–1163.

23. Olberg, D.E.; Arukwe, J.M.; Grace, D.; Hjelstaen, O.K.; Solbakken, M.; Kindberg, G.M.; Cuthbertson, A. One step radiosynthesis of 6-[[18]F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([18]F-Py-TFP): A new prosthetic group for efficient labeling of biomolecules with fluorine-18. J. Med. Chem. 2010, 53, 1732–1740.

24. Koudih, R.; Kostikov, A.; Kovacevic, M.; Jolly, D.; Bernard-Gauthier, V.; Chin, J.; Jurkschat, K.; Wangler, C.; Wangler, B.; Schirrmacher, R. Automated radiosynthesis of N-succinimidyl 3-(di-tert-butyl)[18]Ffluorosilyl)benzoate ([18]FSiFB) for peptides and proteins radiolabeling for positron emission tomography. Appl. Radiat. Isot. 2014, 89, 146–150.
25. Kluba, C.A.; Mindt, T.L. Click-to-Chelate: Development of technetium and rhenium-tricarbonyl labeled radiopharmaceuticals. Molecules 2013, 18, 3206–3226.

26. Marik, J.; Sutcliffe, J.L. Rapid preparation of [18F]fluoropeptides using Cu(I) catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 2006, 47, 6681–6684.

27. Glaser, M.; Aarstad, E. “Click labeling” with 2-[18F]fluoroethylazide for positron emission tomography. Bioconjug Chem. 2007, 18, 989–993.

28. Arumugam, S.; Chin, J.; Schirrmacher, R.; Popik, V.V.; Kostikov, A.P. [18F]azadibenzo[cyclooctyne ([18F]ADIBO): A biocompatible radioactive labeling synthon for peptides using catalyst free [3+2] cycloaddition. Bioorg Med. Chem. Lett. 2011, 21, 6987–6991.

29. Campbell-Verduyn, L.S.; Mirfeizi, L.; Schoonen, A.K.; Dierckx, R.A.; Elsinga, P.H.; Feringa, B.L. Strain-promoted copper-free “click” chemistry for [18F] labeled peptides. Angew. Chem. Int. Ed. Engl. 2011, 50, 11117–11120.

30. Iwata, R.; Pascali, C.; Bogni, A.; Horvath, G.; Kovacs, Z.; Yanai, K.; Ido, T. A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides. Appl. Radiat. Isot. 2000, 52, 87–92.

31. Poethko, T.; Schottelius, M.; Thumshirn, G.; Hersel, U.; Herz, M.; Henriksen, G.; Kessler, H.; Schweiger, M.; Wester, H.J. Two-step methodology for high-yield routine radiohalogenation of peptides: [18F]-labeled RGD and octreotide analogs. J. Nucl. Med. 2004, 45, 892–902.

32. Bruus-Jensen, K.; Poethko, T.; Schottelius, M.; Hauser, A.; Schweiger, M.; Wester, H.J. Chemoselective hydrazine formation between HYNIC-functionalized peptides and [18F]-fluorinated aldehydes. Nucl. Med. Biol. 2006, 33, 173–183.

33. Hultsch, C.; Schottelius, M.; Auernheimer, J.; Alke, A.; Wester, H.J. 18F-Fluoroglycosylation of peptides, exemplified on cyclo(RGDfK). Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1469–1474.

34. Wuest, F.; Hultsch, C.; Berndt, M.; Bergmann, R. Direct labelling of peptides with 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG). Bioorg. Med. Chem. Lett. 2009, 19, 5426–5428.

35. Prante, O.; Einsiedel, J.; Haubner, R.; Gmeiner, P.; Wester, H.J.; Kuwert, T.; Maschauer, S. 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]-fluoroglucopyranosyl phenyllithiosulfonate: A thiol-reactive agent for the chemoselective 18F-glycosylation of peptides. Bioconjug. Chem. 2007, 18, 254–262.

36. Maschauer, S.; Prante, O. A series of 2-O-trifluoromethylsulfonyl-O-mannopyranosides as precursors for concomitant 18F-labeling and glycosylation by click chemistry. Carbohydr. Res. 2009, 344, 753–761.

37. Shue, C.Y.; Wolf, A.; Haintfeld, J.F. Synthesis of 18F-labelled N-(p-[18F]fluorophenyl)maleimide and its derivatives for labelling monoclonal antibody with 18F. J. Label. Compd. Radiopharm. 1989, 26, 287–289.

38. Toyokuni, T.; Walsh, J.C.; Dominguez, A.; Phelps, M.E.; Barrio, J.R.; Gambhir, S.S.; Satyamurthy, N. Synthesis of a new heterobifunctional linker, N-[4-(aminoxy)butyl]maleimide, for facile access to a thiol-reactive 18F-labeling agent. Bioconjug. Chem. 2003, 14, 1253–1259.

39. Wuest, F.; Berndt, M.; Bergmann, R.; van den Hoff, J.; Pietzsch, J. Synthesis and application of [18F]FDG-maleimidehexyloxime ([18F]FDG-MHO): A [18F]FDG-based prosthetic group for the chemoselective 18F-labeling of peptides and proteins. Bioconjug. Chem. 2008, 19, 1202–1210.

40. Ivkovka, L.; Wangler, B.; Schirrmacher, E.; Schirrmacher, R.; Quandt, G.; Boening, G.; Schurmann, M.; Jurkschat, K. para-Functionalized aryl-di-tert-butylfluorosilanes as potential labeling synths for [18F] radiopharmaceuticals. Chem. Pharmaceut. 2009, 15, 2140–2147.

41. Chansanapak, K.; Wang, M.; Wu, Z.; Zaman, R.; Li, Z.; Gabbai, F.P. [18F]-NHC-BF3 adducts as water stable radio-prosthetic groups for PET imaging. Chem. Commun. 2015, 51, 12439–12442.

42. Glaser, M.; Karlson, H.; Solbakken, M.; Arukwe, J.; Brady, F.; Luthra, S.K.; Cuthbertson, A. 18F-fluorothiols: A new approach to label peptides chemoselectively as potential tracers for positron emission tomography. Bioconjug. Chem. 2004, 15, 1447–1453.

43. Wangler, B.; Quandt, G.; Ivkovka, L.; Schirrmacher, E.; Wangler, C.; Boening, G.; Hacker, M.; Schmoeckel, M.; Jurkschat, K.; Bartenstein, P.; et al. Kit-like 18F-labeling of proteins: Synthesis of 4-(di-tert-butyl)[18F]fluoro[3H]benzenethiol (Si[18F]FA-SH) labeled rat serum albumin for blood pool imaging with PET. Bioconjug. Chem. 2009, 20, 317–321.

44. Kumar, K.; Ghosh, A. 18F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography Imaging Pharmaceuticals. Bioconjug. Chem. 2018, 29, 953–975.

45. Wan, W.; Guo, N.; Pan, D.; Yu, C.; Weng, Y.; Luo, S.; Ding, H.; Xu, Y.; Wang, L.; Lang, L.; et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J. Nucl. Med. 2013, 54, 691–698.
46. Wu, C.; Yue, X.; Lang, L.; Kiesewetter, D.O.; Li, F.; Zhu, Z.; Niu, G.; Chen, X. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-AlphaTIDE II and differentiation with tumors. *Theranostics* 2014, 4, 546–555.
47. Yu, C.; Pan, D.; Mi, B.; Xu, Y.; Lang, L.; Niu, G.; Yang, M.; Wan, W.; Chen, X. 18F-AlphaTIDE II PET/CT in healthy human volunteers and patients with brain metastases. *Eur. J. Nucl. Med. Mol. Imaging* 2015, 42, 2021–2028.
48. Long, T.; Yang, N.; Zhou, M.; Chen, D.; Li, Y.; Li, J.; Tang, Y.; Liu, Z.; Li, Z.; Hu, S. Clinical Application of 18F-All-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms. *Clin. Nucl. Med.* 2019, 44, 452–458.
49. Niedermoser, S.; Chin, J.; Wangler, C.; Kostikov, A.; Bernard-Gauthier, V.; Vogler, N.; Soucy, J.P.; McEwan, A.J.; Schirrmacher, R.; Wangler, B. In Vivo Evaluation of 18F-SiAlin-Modified TATE: A Potential Challenge for 68Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. *J. Nucl. Med.* 2015, 56, 1100–1105.
50. Sundin, J.; Tolmachev, V.; Kozirowski, J.; Carlsson, J.; Lundqvist, H.; Welt, S.; Larson, S.; Sundin, A. High yield direct 82Br-bromination of monoclonal antibodies using chloromine-T. *Nucl. Med. Biol.* 1999, 26, 923–929.
51. McElvany, K.D.; Welch, M.J. Characterization of bromine-77-labeled proteins prepared using bromoperoxidase. *J. Nucl. Med.* 1980, 21, 953–960.
52. Knight, L.C.; Harwig, S.L.; Welch, M.J. In vitro stability and in vivo clearance of fibrinogen or serum albumin labeled with 78Br, 82Br, or 125I by direct or indirect synthetic methods. *J. Nucl. Med.* 1977, 18, 282–288.
53. Wilbur, D.S.; Hylarides, M.D. Radiolabeling of a monoclonal antibody with N-succinimidyl para-[78Br]bromobenzoate. *Int. J. Radiat. Appl. Instrum. B* 1991, 18, 363–365.
54. Lang, L.; Li, W.; Jia, H.M.; Fang, D.C.; Zhang, S.; Sun, X.; Zhu, L.; Ma, Y.; Shen, B.; Kiesewetter, D.O.; et al. New Methods for Labeling RGD Peptides with Bromine-76. *Theranostics* 2011, 1, 341–353.
55. Tolmachev, V. Radiobromine-labelled tracers for positron emission tomography: Possibilities and pitfalls. *Curr. Radiopharm.* 2011, 4, 76–89.
56. Coenen, H.H.; Mertens, J.; Maziere, B. *Radioiodination Reactions for Pharmaceuticals—Compendium for Effective Synthesis Strategies*; Springer: Dordrecht, the Netherlands, 2006.
57. Langone, J.J. Radiiodination by use of the Bolton-Hunter and related reagents. *Methods Enzym.* 1980, 70, 221–247.
58. Garg, P.K.; Garg, S.; Zalutsky, M.R. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzene: Synthesis and potential utility for the radioidination of monoclonal antibodies. *Nucl. Med. Biol.* 1993, 20, 379–387.
59. Smit, J.A.; Myburgh, J.A.; Neirinckx, R.D. Specific inactivation of sensitized lymphocytes in vitro using antigens labelled with astatine-211. *Clin. Exp. Immunol.* 1973, 14, 107–116.
60. Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical experience with α-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitumoral monoclonal antibody 81C6. *J. Nucl. Med.* 2008, 49, 30–38.
61. Zalutsky, M.R.; Zhao, X.G.; Alston, K.L.; Bigner, D. High-level production of α-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use. *J. Nucl. Med.* 2001, 42, 1508–1515.
62. Andersson, H.; Cedekerantz, E.; Back, T.; Divgi, C.; Elgqvist, J.; Himmelman, J.; Horvath, G.; Jacobsson, L.; Jensen, H.; Lindegren, S.; et al. Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of 211At-MX35 F(ab’)2—A phase I study. *J. Nucl. Med.* 2009, 50, 1153–1160.
63. Hallqvist, A.; Bergmark, K.; Back, T.; Andersson, H.; Dahm-Kahler, P.; Johansson, M.; Lindegren, S.; Jensen, H.; Jacobsson, L.; Hultborn, R.; et al. Intraperitoneal alpha-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. *J. Nucl. Med.* 2019, 60, 1073–1079.
64. Lindegren, S.; Frost, S.; Back, T.; Haglund, E.; Elgqvist, J.; Jensen, H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamido immunoconjugate. *J. Nucl. Med.* 2008, 49, 1537–1545.
65. Guerard, F.; Gestin, J.F.; Brechbied, M.W. Production of 2[211At]-astatinated radiopharmaceuticals and applications in targeted alpha-particle therapy. *Cancer Biother. Radiopharm.* 2013, 28, 1–20.
66. Ludwig, R.; Fischer, S.; Dreyer, R.; Jacobi, R.; Berger, J. Complex formation equilibria between astatine(I) and sulphur-containing chelating ligands. *Polyhedron* 1991, 10, 11–17.
67. Yordanov, A.T.; Deal, K.; Gemestani, K.; Kobayashi, H.; Herring, B.; Waldmann, T.A.; Brechbiel, M.W. Synthesis and biodistribution study of a new $^{211}$At-calix[4]arene complex. J. Lab. Compd. Radiopharm. 2000, 43, 1219–1225.

68. McLendon, R.E.; Archer, G.E.; Larsen, R.H.; Akabani, G.; Bigner, D.D.; Zalutsky, M.R. Radiotoxicity of systemically administered $^{211}$At-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis. Int. J. Radiat Oncol. Biol. Phys. 1999, 45, 491–499.

69. Kiess, A.P.; Minn, I.; Vaidyanathan, G.; Hobbs, R.F.; Josefsson, A.; Shen, C.; Brummer, M.; Chen, Y.; Choi, J.; Koumarianou, E.; et al. (2S)-2-(3-(1-Carboxy-5-(4-$^{211}$At-Astatoenaminodio)-pentylo)-ureido)-pentanediolic Acid for PSMA-Targeted alpha-Particle Radiopharmaceutical Therapy. J. Nucl. Med. 2016, 57, 1569–1575.

70. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Vessella, R.L.; Wedge, T.; Hawthorne, M.F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjug Chem. 2007, 18, 1226–1240.

71. Anderson, C.J.; Fardani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. Cancer Biother. Radiopharm. 2009, 24, 379–393.

72. Wu, Y.; Zhang, X.; Xiong, Z.; Cheng, Z.; Fisher, D.R.; Liu, S.; Gambhir, S.S.; Chen, X. microPET imaging of glial integrin $\alpha\beta_3$ expression using $^{64}$Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 2005, 46, 1707–1718.

73. Chen, X.; Hou, Y.; Tohme, M.; Park, R.; Khanaldyyan, V.; Gonzales-Gomez, I.; Bading, J.R.; Laug, W.E.; Conti, P.S. Pegylated Arg-Gly-Asp peptide: $^{64}$Cu labeling and PET imaging of brain tumor $\alpha\beta_3$-integrin expression. J. Nucl. Med. 2004, 45, 1776–1783.

74. Bass, L.A.; Wang, M.; Welch, M.J.; Anderson, C.J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug. Chem. 2000, 11, 527–532.

75. Cai, Z.; Anderson, C.J. Chelators for copper radionuclides in positron emission tomography radiotherapeutics. J. Label. Compd. Radiopharm. 2014, 57, 224–230.

76. Dumont, R.A.; Deininger, F.; Haubner, R.; Maecke, H.R.; Weber, W.A.; Fani, M. Novel $^{64}$Cu- and $^{68}$Ga-labeled RGD conjugates show improved PET imaging of $\alpha\beta_3$ integrin expression and facile radiosynthesis. J. Nucl. Med. 2011, 52, 1276–1284.

77. Ghosh, S.C.; Pinkston, K.L.; Robinson, H.; Harvey, B.R.; Wilganowski, N.; Gore, K.; Sevick-Muraca, E.M.; Azhdarinia, A. Comparison of DOTA and NODAGA as chelators for $^{64}$Cu-labeled immunoconjugates. Nucl. Med. Biol. 2015, 42, 177–183.

78. Sevcenco, S.; Klingler, H.C.; Eredics, K.; Friedl, A.; Schneeweiss, J.; Knoll, P.; Kunit, T.; Lusuardi, L.; Mirzaei, S. Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer. Adv. Ther. 2018, 35, 779–784.

79. Boal, A.K.; Rosenzweig, A.C. Structural biology of copper trafficking. Chem. Rev. 2009, 109, 4760–4779.

80. Zeglis, B.M.; Lewis, J.S. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 2011, 40, 6168–6195.

81. Dos Santos, J.C.; Beijer, B.; Bauder-Wust, U.; Schafer, M.; Leotta, K.; Eder, M.; Benesova, M.; Kleist, C.; Giesel, F.; Kratochwil, C.; et al. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. J. Nucl. Med. 2019, doi:10.2967/jnumed.119.229054.

82. Price, E.W.; Orvig, C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2014, 43, 260–290.

83. Liu, S.; Vorobyova, I.; Park, R.; Conti, P.S. Biodistribution and Radiation Dosimetry of the Integrin Marker $^{64}$Cu-BaBAsar-RGD2 Determined from Whole-Body PET/CT in a Non-human Primate. Front. Phys. 2017, doi:10.3389.fphy.2017.00054.

84. International Atomic Energy Agency (IAEA), Gallium-68 Cyclotron Production, IAEA-TECDOC-1863, IAEA, Vienna, Austria, 2019.

85. Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W.E.; Wangler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. $^{68}$Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 2012, 23, 688–697.

86. Knetsch, P.A.; Petrik, M.; Griesinger, C.M.; Rangger, C.; Fani, M.; Kiesenheimer, C.; von Guggenberg, E.; Piclher, B.J.; Virgolini, I.; Decristoforo, C.; et al. $^{68}$GaNODAGA-RGD for imaging $\alpha\beta_3$ integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1303–1312.

87. Notni, J.; Simecek, J.; Hermann, P.; Wester, H.J. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chemistry 2011, 17, 14718–14722.
98. Notni, J.; Pohle, K.; Wester, H.J. Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of ⁶⁸Ga-TRAP(RGD). *Nucl. Med. Biol.* **2013**, *40*, 33–41.
99. Simecek, J.; Zemek, O.; Hermann, P.; Notni, J.; Wester, H.J. Tailored Gallium(III) chelator NOPO: Synthesis, characterization, bioconjugation, and application in preclinical Ga-68-PET imaging. *Mol. Pharm.* **2014**, *11*, 3893–3903.
100. Waldron, B.P.; Parker, D.; Burchardt, C.; Yuft, D.S.; Zimny, M.; Roesch, F. Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. *Chem. Commun.* **2013**, *49*, 579–581.
101. Knetsch, P.A.; Zhai, C.; Rangger, C.; Blatzer, M.; Haas, H.; Kaeopookum, P.; Haubner, R.; Decristoforo, C. [⁶⁸Ga]FSC-(RGD): a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation. *Nucl. Med. Biol.* **2015**, *42*, 115–122.
102. Kaeopookum, P.; Petrik, M.; Summer, D.; Klinger, M.; Zhai, C.; Rangger, C.; Haubner, R.; Haas, H.; Hajducz, M.; Decristoforo, C. Comparison of ⁶⁸Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold. *Nucl. Med. Biol.* **2019**, *78-79*, 1–10.
103. Dijkers, E.C.; Kosterink, J.G.; Rademaker, A.P.; Perk, L.R.; van Dongen, G.A.; Bart, J.; de Jong, J.R.; de Vries, E.G.; Lub-de Hooge, M.N. Development and characterization of clinical-grade ⁷⁶Zr-trastuzumab for HER2/neu immunoPET imaging. *J. Nucl. Med.* **2009**, *50*, 974–981.
104. Aerts, H.J.; Dubois, I.; Perk, L.; Vermaelen, P.; van Dongen, G.A.; Wouters, B.G.; Lambin, P. Disparity between in vivo EGFR expression and ⁶⁸Zr-labeled cetuximab uptake assessed with PET. *J. Nucl. Med.* **2009**, *50*, 123–131.
105. Nagengast, W.B.; de Korte, M.A.; Oude Munnink, T.H.; Timmer-Bosscha, H.; den Dunnen, W.F.; Hollema, H.; de Jong, J.R.; Jensen, M.R.; Quadt, C.; Garcia-Echeverria, C.; et al. ⁷⁶Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. *J. Nucl. Med.* **2010**, *51*, 761–767.
106. Zhang, Y.; Hong, H.; Cai, W. PET tracers based on Zirconium-89. *Curr. Radiopharm.* **2011**, *4*, 131–139.
107. Heskamp, S.; Raave, R.; Boerman, O.; Rijpkema, M.; Goncalves, V.; Denat, F. ⁷⁹Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art ⁷⁹Zr Radiochemistry. *Bioconjug. Chem.* **2017**, *28*, 2211–2223.
108. Patra, M.; Bauman, A.; Mari, C.; Fischer, C.A.; Blaque, O.; Häussinger, D.; Gasser, G.; Mindt, T.L. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes. *Chem. Commun.* **2014**, *50*, 11523–11525.
109. Vugts, D.J.; Klaver, C.; Sewing, C.; Poot, A.J.; Adamzek, K.; Huegli, S.; Mari, C.; Visser, G.W.M.; Valverde, I.E.; Gasser, G.; et al. Comparison of the octadentate bifunctional chelator DFO-pPh-NCS and the clinically used hexadentate bifunctional chelator DFO-pHe-NCS for ⁷⁹Zr-immuno-PET. *Eur. J. Nucl. Med. Mol. Imaging* **2017**, *44*, 286–295.
110. Petrik, M.; Zhai, C.; Novy, Z.; Urbanek, L.; Haas, H.; Decristoforo, C. In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. *Mol. Imaging Biol.* **2016**, *18*, 344–352.
111. Deri, M.A.; Ponnala, S.; Zeglis, B.M.; Pohl, G.; Dannenberg, J.J.; Lewis, J.S.; Francesconi, L.C. Alternative chelator for ⁷⁹Zr radiopharmaceuticals: Radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). *J. Med. Chem.* **2014**, *57*, 4849–4860.
112. Pandya, D.N.; Bhatt, N.; Yuan, H.; Day, C.S.; Ehrmann, B.M.; Wright, M.; Bierbach, U.; Wadas, T.J. Zirconium tetraazamacrocyclic complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. *Chem. Sci.* **2017**, *8*, 2309–2314.
113. Emmett, L.; Willson, K.; Violet, J.; Shin, J.; Blanksby, A.; Lee, J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: A review of the current literature and discussion of practical aspects. *J. Med. Radiat. Sci.* **2017**, *64*, 52–60.
114. Sinnes, J.P.; Nagel, J.; Rosch, F. AAZTA³/AAZTA⁵-TOC: Synthesis and radiochemical evaluation with ⁶⁸Ga, ⁶⁷Se and ⁶⁸Lu. *EJNMMI Radiopharm. Chem.* **2019**, *4*, 18.
115. Price, E.W.; Zeglis, B.M.; Cawthray, J.F.; Ramogida, C.F.; Ramos, N.; Lewis, J.S.; Adam, M.J.; Orvig, C. Hexoctapa-trastuzumab: Versatile acyclic chelate system for ¹¹¹In and ¹⁷⁷Lu imaging and therapy. *J. Am. Chem. Soc.* **2013**, *135*, 12707–12721.
116. Kang, C.S.; Sun, X.; Jia, F.; Song, H.A.; Chen, Y.; Lewis, M.; Chong, H.S. Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of ⁶⁸Y and ¹⁷⁷Lu for targeted radioimmunotherapy. *Bioconjug. Chem.* **2012**, *23*, 1775–1782.
107. Ferrier, M.G.; Radchenko, V.; Wilbur, D.S. Radiochemical aspects of alpha emitting radionuclides for medical application. *Radiochim. Acta* **2019**, *107*, 1065–1085.

108. Chappell, L.L.; Deal, K.A.; Dadachova, E.; Brechbiel, M.W. Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for $^{225}$Ac radioimmunotherapy applications. *Bioconjug. Chem.* **2000**, *11*, 510–519.

109. Morgenstern, A.; Apostolidis, C.; Kratochwil, C.; Sathekege, M.; Krolicki, L.; Bruchertseifer, F. An Overview of Targeted Alpha Therapy with $^{225}$Actinium and $^{212}$Bismuth. *Curr. Radiopharm.* **2018**, *11*, 200–208.

110. Scheinberg, D.A.; McDevitt, M.R. Actinium-225 in targeted alpha-particle therapeutic applications. *Curr. Radiopharm.* **2011**, *4*, 306–320.

111. Kratochwil, C.; Bruchertseifer, F.; Giesel, F.L.; Weis, M.; Verburg, F.A.; Mottaghy, F.; Kopka, K.; Apostolidis, C.; Haberkorn, U.; Morgenstern, A. $^{225}$Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. *J. Nucl. Med.* **2016**, *57*, 1941–1944.

112. Thiele, N.A.; Brown, V.; Kelly, J.M.; Amor-Coarasa, A.; Jermilova, U.; MacMillan, S.N.; Nikolopoulos, A.; Ponnala, S.; Ramogida, C.F.; Robertson, A.K.H.; et al. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. *Angew. Chem. Int. Ed. Engl.* **2017**, *56*, 14712–14717.

113. Wei, L.; Ye, Y.; Wadas, T.J.; Lewis, J.S.; Welch, M.J.; Achilefu, S.; Anderson, C.J. $^{64}$Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: Comparison of their biological activity. *Nucl. Med. Biol.* **2009**, *36*, 277–285.

114. Schjoeth-Eskesen, C.; Nielsen, C.H.; Heissel, S.; Hojrup, P.; Hansen, P.R.; Gillings, N.; Kjaer, A. $^{64}$Cu-labelled trastuzumab: Optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. *J. Label. Compd. Radiopharm.* **2015**, *58*, 227–233.

115. Craft, J.M.; De Silva, R.A.; Lears, K.A.; Andrews, R.; Liang, K.; Achilefu, S.; Rogers, B.E. In vitro and in vivo evaluation of a $^{64}$Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. *Nucl. Med. Biol.* **2012**, *39*, 609–616.

116. Spang, P.; Herrmann, C.; Roesch, B. Bifunctional Gallium-68 Chelators: Past, Present, and Future. *Semin. Nucl. Med.* **2016**, *46*, 373–394.

117. Haubner, R.; Vera, D.R.; Farshchi-Heydari, S.; Helbok, A.; Rangger, C.; Putzer, D.; Virgolini, I.J. Development of $^{89}$Zr-labelled DTPA galactosyl human serum albumin for liver function imaging. *Eur. J. Nucl. Med. Mol. Imaging* **2013**, *40*, 1245–1255.

118. Jeong, J.M.; Hong, M.K.; Chang, Y.S.; Lee, Y.S.; Kim, Y.J.; Cheon, G.J.; Lee, D.S.; Chung, J.K.; Lee, M.C. Preparation of a Promising Angiogenesis PET Imaging Agent: $^{89}$Zr-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice. *J. Nucl. Med.* **2008**, *49*, 830–836.

119. Verel, I.; Visser, G.W.; Boellaard, R.; Stigter-van Walsum, M.; Snow, G.B.; van Dongen, G.A. $^{89}$Zr immuno-PET: Comprehensive procedures for the production of $^{89}$Zr-labeled monoclonal antibodies. *J. Nucl. Med.* **2003**, *44*, 1271–1281.

120. Zhai, C.; He, S.; Ye, Y.; Rangger, C.; Kaeopookum, P.; Summer, D.; Haas, H.; Kremsner, L.; Lindner, H.; Foster, J.; et al. Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarimine C-Based Chelators for Radiolabeling with Zirconium-89. *Biomolecules* **2019**, *9*, 91.

121. Breeman, W.A.; De Jong, M.; Visser, T.J.; Erion, J.L.; Krenning, E.P. Optimising conditions for radiolabelling of DOTA-peptides with $^{68}$Y, $^{111}$In and $^{177}$Lu at high specific activities. *Eur. J. Nucl. Med. Mol. Imaging* **2003**, *30*, 917–920.

122. Robertson, A.K.H.; Ramogida, C.F.; Schaffer, P.; Radchenko, V. Development of $^{225}$Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences. *Curr. Radiopharm.* **2018**, *11*, 156–172.

123. Sun, X.; Li, Y.; Liu, T.; Li, Z.; Zhang, X.; Chen, X. Peptide-based imaging agents for cancer detection. *Adv. Drug Deliv. Rev.* **2017**, *110–111*, 38–51.

124. Jackson, I.M.; Scott, P.J.H.; Thompson, S. Clinical Applications of Radiolabeled Peptides for PET. *Semin. Nucl. Med.* **2017**, *47*, 493–523.

125. Johnbeck, C.B.; Knigge, U.; Kjaer, A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: Current status and review of the literature. *Future Oncol.* **2014**, *10*, 2259–2277.

126. Hofmann, M.; Maecke, H.; Borner, R.; Weckesser, E.; Schofiski, P.; Oei, L.; Schumacher, J.; Henze, M.; Heppeler, A.; Meyer, J.; et al. Biokinetics and imaging with the somatostatin receptor PET radioligand $^{68}$Ga-DOTATOC: Preliminary data. *Eur. J. Nucl. Med.* **2001**, *28*, 1751–1757.
127. Poeppel, T.D.; Binse, I.; Petersenn, S.; Lahner, H.; Schott, M.; Antoch, G.; Brandau, W.; Bockisch, A.; Boy, C. 64Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. *J. Nucl. Med.* 2011, 52, 1864–1870.

128. Kabasakal, I.; Demirci, E.; Oacak, M.; Decristoforo, C.; Araman, A.; Ozsoy, Y.; Uslu, I.; Kanmaz, B. Comparison of 64Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. *Eur. J. Nucl. Med. Mol. Imaging* 2012, 39, 1271–1277.

129. Wild, D.; Schmitt, J.S.; Ginj, M.; Macke, H.R.; Bernard, B.F.; Krenning, E.; De Jong, M.; Wenger, S.; Reubi, J.C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. *Eur. J. Nucl. Med. Mol. Imaging* 2003, 30, 1338–1347.

130. Pauwels, E.; Cleeren, F.; Bornmans, G.; Deroose, C.M.; Somatostatin receptor PET ligands—The next generation for clinical practice. *Am. J. Nucl. Med. Mol. Imaging* 2018, 8, 311–331.

131. Anderson, C.J.; Dehdashiti, F.; Cutler, P.D.; Schwarz, S.W.; Laforest, R.; Bass, L.A.; Lewis, J.S.; McCarthy, D.W. 68Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. *J. Nucl. Med.* 2001, 42, 213–221.

132. Pfeifer, A.; Knigge, U.; Mortensen, J.; Oturai, P.; Berthelsen, A.K.; Løft, A.; Binderup, T.; Rasmussen, P.; Elema, D.; Klausen, T.L.; et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: First-in-humans study. *J. Nucl. Med.* 2012, 53, 1207–1215.

133. Johnbeck, C.B.; Knigge, U.; Løft, A.; Berthelsen, A.K.; Mortensen, J.; Oturai, P.; Langer, S.W.; Elema, D.R.; Kjaer, A. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. *J. Nucl. Med.* 2017, 58, 451–457.

134. Schottelius, M.; Poethko, T.; Herz, M.; Reubi, J.C.; Kessler, H.; Schwaiger, M.; Wester, H.J. First 18F-labeled tracer suitable for routine clinical imaging of somatostatin receptor-expressing tumors using positron emission tomography. *Clin. Cancer Res.* 2004, 10, 3593–3606.

135. Meietschläger, G.; Poethko, T.; Stahl, A.; Wolf, I.; Scheidhauer, K.; Schottelius, M.; Herz, M.; Wester, H.J.; Schwaiger, M. Gluc-Lys([18F]F)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. *J. Nucl. Med.* 2006, 47, 566–573.

136. Iddon, L.; Leyton, J.; Indrevoll, B.; Glaser, M.; Robins, E.G.; George, A.J.; Cuthbertson, A.; Luthra, S.K.; Aboagye, E.O. Synthesis and in vitro evaluation of [18F]fluoroethyl triazol labelled [Tyr3]octreotide analogues using click chemistry. *Bioorg. Med. Chem. Lett.* 2011, 21, 3122–3127.

137. Dubash, S.R.; Keat, N.; Mapelli, P.; Twyman, F.; Carroll, L.; Kozlowski, K.; Al-Nahhas, A.; Saleem, A.; Huiban, M.; Janisch, R.; et al. Clinical Translation of a Click-Labeled 18F-Octreotide Radioligand for Imaging Neuroendocrine Tumors. *J. Nucl. Med.* 2016, 57, 1207–1213.

138. Waldmann, C.M.; Stuparu, A.D.; van Dam, R.M.; Slavik, R. The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 68Ga-labeled Somatostatin Analog Development. *Theranostics* 2019, 9, 1336–1347.

139. Ilhan, H.; Lindner, S.; Todica, A.; Cyran, C.C.; Tilling, R.; Auernhammer, C.J.; Spitzweg, C.; Boeck, S.; Unterrainer, M.; Gildehaus, F.J.; et al. Biodistribution and first clinical results of 68Ga-SiF-Al-TATE PET: A novel 68Ga-labeled somatostatin analog for imaging of neuroendocrine tumors. *Eur. J. Nucl. Med. Mol. Imaging* 2019, doi:10.1007/s00259-019-04501-6.

140. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Macke, H.R.; Reubi, J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. *Proc. Natl. Acad. Sci. USA* 2006, 103, 16436–16441.

141. Fani, M.; Braun, F.; Waser, B.; Beetschen, K.; Cescato, R.; Erchegyi, J.; Rivier, J.E.; Weber, W.A.; Maecke, H.R.; Reubi, J.C. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. *J. Nucl. Med.* 2012, 53, 1481–1489.

142. Nicolas, G.P.; Schreiter, N.; Kaul, F.; Uiters, J.; Bouterfa, H.; Kaufmann, J.; Erlanger, T.E.; Cathomas, R.; Christ, E.; Fani, M.; et al. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. *J. Nucl. Med.* 2018, 59, 915–921.

143. Basu, S.; Parghane, R.V.; Banerjee, S. Availability of both [177Lu]Lu-DOTA-TATE and [89Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: Can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors? *Eur. J. Nucl. Med. Mol. Imaging* 2019, doi:10.1007/s00259-019-04546-7.

144. Ballal, S.; Yadav, M.P.; Bal, C.; Sahoo, R.K.; Tripathi, M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to
125I-DOTATATE PRRT: First clinical experience on the efficacy and safety. *Eur. J. Nucl. Med. Mol. Imaging* 2019, doi:10.1007/s00259-019-04567-2.

145. Dalm, S.U.; Nonnekens, J.; Doeswijk, G.N.; de Blois, E.; van Gent, D.C.; Konijnenberg, M.W.; de Jong, M. Comparison of the Therapeutic Response to Treatment with a 125I-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. *J. Nucl. Med.* 2016, 57, 260–265.

146. Reidy-Lagnes, D.; Pandit-Taskar, N.; O’Donoghue, J.A.; Krebs, S.; Staton, K.D.; Lyashchenko, S.K.; Lewis, J.S.; Raj, N.; Gonen, M.; Lohrmann, C.; et al. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 125I-Lu-Satoreotide Tetraextend. *Clin. Cancer Res.* 2019, 25, 6939–6947.

147. Kozikowski, A.P.; Zhang, J.; Nan, F.; Petukhov, P.A.; Grajkowska, E.; Wroblewski, J.T.; Yamamoto, T.; Bzdegaj, T.; Wroblewska, B.; Neale, J.H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents. *J. Med. Chem.* 2004, 47, 1729–1738.

148. Foss, C.A.; Mease, R.C.; Fan, H.; Wang, Y.; Ravert, H.T.; Dannals, R.F.; Olszewski, R.T.; Heston, W.D.; Kozikowski, A.P.; Pomper, M.G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. *Clin. Cancer Res.* 2005, 11, 4022–4028.

149. Banerjee, S.R.; Foss, C.A.; Castanares, M.; Mease, R.C.; Byun, Y.; Fox, J.J.; Hilton, J.; Lupold, S.E.; Kozikowski, A.P.; Pomper, M.G. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). *J. Med. Chem.* 2008, 51, 4504–4517.

150. Chen, Y.; Foss, C.A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J.J.; Castanares, M.; Lupold, S.E.; Babich, J.W.; Mease, R.C.; et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. *J. Med. Chem.* 2008, 51, 7933–7943.

151. Benesova, M.; Schafer, M.; Bauder-Wust, U.; Afshar-Oromieh, A.; Kratochwil, C.; Mier, W.; Haberkorn, U.; Kopka, K.; Eder, M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. *J. Nucl. Med.* 2015, 56, 914–920.

152. Cardinale, J.; Schafer, M.; Benesova, M.; Bauder-Wust, U.; Leotta, K.; Eder, M.; Neels, O.C.; Haberkorn, U.; Giesel, F.L.; Kopka, K. Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. *J. Nucl. Med.* 2017, 58, 425–431.

153. Wester, H.J.; Schottelius, M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. *Semin. Nucl Med.* 2019, 49, 302–312.

154. Afshar-Oromieh, A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Mier, W.; Haufe, S.; Debus, N.; Eder, M.; Eisenhut, M.; Schafer, M.; et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. *Eur J. Nucl. Med. Mol. Imaging* 2017, 44, 1258–1268.

155. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; et al. PET imaging with a 68Ga-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. *Eur. J. Nucl. Med. Mol. Imaging* 2013, 40, 486–495.

156. Virgolini, I.; Decristoforo, C.; Haug, A.; Fanti, S.; Uprimny, C. Current status of theranostics in prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 471–495.

157. De Visschere, P.J.L.; Standaert, C.; Futterer, J.J.; Villeirs, G.M.; Panebianco, V.; Walz, J.; Maurer, T.; Hadaschik, B.A.; Lecouvret, F.E.; Giannarini, G.; et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. *Eur. Urol. Oncol.* 2019, 2, 47–76.

158. Weineisen, M.; Schottelius, M.; Simecek, J.; Baum, R.P.; Yildiz, A.; Beykan, S.; Kulkarni, H.R.; Lassmann, M.; Klette, I.; Eiber, M.; et al. 68Ga- and 125I-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. *J. Nucl. Med.* 2015, 56, 1169–1176.

159. Zhang, A.X.; Murelli, R.P.; Barinka, C.; Michel, J.; Cocelea, A.; Jorgensen, W.L.; Lubkowski, J.; Spiegel, D.A. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. *J. Am. Chem. Soc.* 2010, 132, 12711–12716.

160. McCarthy, M.; Langton, T.; Kumar, D.; Campbell, A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2017, 44, 1455–1462.

161. Derlin, T.; Schmuck, S.; Juhl, C.; Teichert, S.; Zorgiebel, J.; Wester, H.J.; Schneefeld, S.M.; Walte, A.C.A.; Thackeray, J.T.; Ross, T.L.; et al. Imaging Characteristics and First Experience of 68Ga]THP-PSMA, a Novel
Pharmaceuticals 2020, 13, 22

Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T. Mol. Imaging Biol. 2018, 20, 650–658.

163. Green, M.A.; Hutchins, G.D.; Bahler, C.D.; Tann, M.; Mathias, C.J.; Territo, W.; Sims, J.; Polson, H.; Alexoff, D.; Eckelman, W.C.; et al. [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence. Mol. Imaging Biol. 2019, doi:10.1007/s11307-019-01421-7.

164. Chen, Y.; Pullambhatla, M.; Foss, C.A.; Byun, Y.; Nimmagadda, S.; Senthamizhchelvan, S.; Sgouros, G.; Mease, R.C.; Pomper, M.G. 2-(3-[1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-penty]-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 2011, 17, 7645–7653.

165. Malik, N.; Baur, B.; Winter, G.; Reske, S.N.; Beer, A.J.; Solbach, C. Radiofluorination of PSMA-HBED via Al[18F](2+) Chelation and Biological Evaluations In Vitro. Mol. Imaging Biol. 2015, 17, 777–785.

166. Behr, S.C.; Aggarwal, R.; VanBroecklin, H.F.; Flavell, R.R.; Gao, K.; Small, E.J.; Blecha, J.; Jivan, S.; Hope, T.A.; Simko, J.P.; et al. Phase I Study of CTT1057, an [18F]-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J. Nucl. Med. 2019, 60, 910–916.

167. Zlatopolskiy, B.D.; Endepols, H.; Krapf, P.; Gulyiev, M.; Urusova, E.A.; Richarz, R.; Hobberg, M.; Dietlein, M.; Drzegha, A.; Neumaier, B. Discovery of [18F]-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. J. Nucl. Med. 2019, 60, 817–823.

168. Dietlein, F.; Kob, C.; Neubauer, S.; Schmidt, M.; Stocker, S.; Fischer, T.; Schomacker, K.; Heidenreich, A.; Zlatopolskiy, B.D.; Neumaier, B.; et al. PSA-Stratified Performance of [18F]- and [68Ga]Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J. Nucl. Med. 2017, 58, 947–952.

169. Giesel, F.L.; Knorr, K.; Spohn, F.; Will, L.; Maurer, T.; Flechsig, P.; Neels, O.; Schiller, K.; Amaral, H.; Weber, W.A.; et al. Detection Efficacy of [18F]-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J. Nucl. Med. 2019, 60, 362–368.

170. Giesel, F.L.; Will, L.; Lawal, I.; Lengana, T.; Kratochwil, C.; Vorster, M.; Neels, O.; Reynke, F.; Haberkon, U.; Kopka, K.; et al. Intraindividual Comparison of [18F]-PSMA-1007 and [18F]DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J. Nucl. Med. 2018, 59, 1076–1080.

171. Dannoos, S.; Ganguly, T.; Cahaya, H.; Gerunth, J.I.; Galliher, M.S.; Beyer, S.K.; Choy, C.J.; Hopkins, M.R.; Regan, M.; Blecha, J.E.; et al. Structure-Activity Relationship of [18F]-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J. Med. Chem. 2016, 59, 5684–5694.

172. Dietlein, F.; Hoehberg, M.; Kob, C.; Zlatopolskiy, B.D.; Krapf, P.; Endepols, H.; Tager, P.; Hammes, J.; Heidenreich, A.; Neumaier, B.; et al. A novel [18F]-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First-in-man observational study and clinical experience with [18F]-JK-PSMA-7 during the first year of application. J. Nucl. Med. 2019, doi:10.2967/jnumed.119.229542.

173. Kersemans, K.; De Man, K.; Courty, J.; Van Royen, T.; Piron, S.; Moerman, L.; Brans, B.; De Vos, F. Automated radiosynthesis of All[18F]PSMA-11 for large scale routine use. Appl. Radiat. Isot. 2018, 135, 19–27.

174. Piron, S.; De Man, K.; Van Laeken, N.; D’Asseler, Y.; Bacher, K.; Kersemans, K.; Ost, P.; Decaestecker, K.; Deseye, P.; Fonteyne, V.; et al. Radiation Dosimetry and Biodistribution of [18F]-PSMA-11 for PET Imaging of Prostate Cancer. J. Nucl. Med. 2019, 60, 1736–1742.

175. Rahbar, K.; Ahmadzadehfar, H.; Boegemann, M. 177Lu-PSMA-617 radioligand therapy in mCRPC: Ready for phase III trial? Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 513–514.

176. Heck, M.M.; Tauber, R.; Schwager, S.; Retz, M.; D’Alessandria, C.; Maurer, T.; Gafita, A.; Wester, H.J.; Gschwend, J.E.; Weber, W.A.; et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur. Urol. 2019, 75, 920–926.

177. Lau, J.; Jacobson, O.; Niu, G.; Lin, K.S.; Benard, F.; Chen, X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjug. Chem. 2019, 30, 487–502.
178. Wang, Z.; Tian, R.; Niu, G.; Ma, Y.; Lang, L.; Szajek, L.P.; Kiesewetter, D.O.; Jacobson, O.; Chen, X. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem. 2018, 29, 3213–3221.

179. Zang, J.; Fan, X.; Wang, H.; Liu, Q.; Wang, J.; Li, H.; Li, F.; Jacobson, O.; Niu, G.; Zhu, Z.; et al. First-in-human study of $^{177}$Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019, 46, 148–158.

180. Chakravarty, R.; Slamoć, C.M.; Dash, A.; Cai, W. Targeted alpha-therapy of prostate cancer using radiolabeled PSMA inhibitors: A game changer in nuclear medicine. Am. J. Nucl. Med. Mol. Imaging 2018, 8, 247–267.

181. Sathekge, M.; Knoesen, O.; Meckel, M.; Modselle, M.; Vorster, M.; Marx, S. $^{213}$Bi-PSMA-617 targeted alpharadionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2017, 44, 1099–1100.

182. Khreish, F.; Ebert, N.; Ries, M.; Maus, S.; Rosar, F.; Bohnenberger, H.; Stemler, T.; Saar, M.; Bartholoma, M.; Ezziddin, S. $^{225}$Ac-PSMA-617/$^{177}$Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: Pilot experience. Eur. J. Nucl. Med. Mol. Imaging 2019, doi:10.1007/s00259-019-04612-0.

183. Fendler, W.P.; Rahbar, K.; Herrmann, K.; Kratochwil, C.; Eiber, M. $^{177}$Lu-PSMA Radioligand Therapy for Prostate Cancer. J. Nucl. Med. 2017, 58, 1196–1200.

184. Chen, H.; Niu, G.; Wu, H.; Chen, X. Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin alphavbeta3. Theranostics 2016, 6, 78–92.

185. Debordeaux, F.; Chansel-Debordeaux, L.; Pinaquy, J.B.; Fernandez, P.; Schulz, J. What about $\alpha_\beta$-integrins in molecular imaging in oncology? Nucl. Med Biol 2018, 62, 31–46.

186. Aumailley, M.; Guerrath, M.; Muller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991, 291, 50–54.

187. Haubner, R.; Wester, H.J.; Reuning, U.; Senekowitsch-Schmidtke, R.; Diefenbach, B.; Kessler, H.; Stocklin, G.; Schwager, M. Radiolabeled $\alpha_\beta$ integrin antagonists: A new class of agents for tumor targeting. J. Nucl. Med. 1999, 40, 1061–1071.

188. Haubner, R.; Wester, H.J.; Weber, W.A.; Mang, C.; Ziegler, S.I.; Goodman, S.L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwager, M. Noninvasive imaging of $\alpha_\beta$ integrin expression using $^{18}$F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001, 61, 1781–1785.

189. Haubner, R.; Weber, W.A.; Beer, A.J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K.F.; Goebel, M.; Hein, R.; Wester, H.J.; et al. Noninvasive visualization of the activated $\alpha_\beta$ integrin in cancer patients by positron emission tomography and $^{18}$F-Galacto-RGD. PLoS Med. 2005, 2, e70.

190. Beer, A.J.; Haubner, R.; Goebel, M.; Luderscheidt, S.; Spilker, M.E.; Wester, H.J.; Weber, W.A.; Schwager, M. Biodistribution and pharmacokinetics of the $\alpha_\beta$-selective tracer $^{18}$F-galacto-RGD in cancer patients. J. Nucl. Med. 2005, 46, 1333–1341.

191. Beer, A.J.; Grosu, A.L.; Carlsen, J.; Kolk, A.; Sarbia, M.; Stangier, I.; Watzlowik, P.; Wester, H.J.; Haubner, R.; Schwager, M. $^{18}$F-galacto-RGD positron emission tomography for imaging of $\alpha_\beta$ expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2007, 13, 6610–6616.

192. Beer, A.J.; Haubner, R.; Sarbia, M.; Goebel, M.; Luderscheidt, S.; Grosu, A.L.; Schnell, O.; Niemeyer, M.; Kessler, H.; Wester, H.J.; et al. Positron emission tomography using $^{18}$F-Galacto-RGD identifies the level of integrin $\alpha_\beta$ expression in man. Clin. Cancer Res. 2006, 12, 3942–3949.

193. Mirfeizi, L.; Walsh, J.; Kolb, H.; Campbell-Verduyn, L.; Diercks, R.A.; Feringa, B.L.; Elsinga, P.H.; de Groot, T.; Sannen, I.; Bormans, G.; et al. Synthesis of $^{18}$F-RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin $\alpha_\beta$ expression in vivo. Nucl. Med. Biol. 2013, 40, 710–716.

194. Glaser, M.; Morrison, M.; Solbakken, M.; Arukwe, J.; Karlsen, H.; Wiggers, U.; Champion, S.; Kindberg, G.M.; Cuthbertson, A. Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel $^{18}$F-fluorinated aldehyde-containing prosthetic groups. Bioconjug. Chem. 2008, 19, 951–957.

195. Haubner, R.; Wester, H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of antiangiogenic therapies. Curr. Pharm. Des. 2004, 10, 1439–1455.

196. Liu, S.; Liu, Z.; Chen, K.; Yan, Y.; Watzlowik, P.; Wester, H.J.; Chin, F.T.; Chen, X. $^{18}$F-labeled galacto and PEGylated RGD dimers for PET imaging of $\alpha_\beta$ integrin expression. Mol. Imaging Biol. 2010, 12, 530–538.
Pharmaceuticals 2020, 13, 22

197. Lang, L.; Li, W.; Guo, N.; Ma, Y.; Zhu, L.; Kiesewetter, D.O.; Shen, B.; Niu, G.; Chen, X. Comparison study of \(^{18}F\)FAI-NOTA-PRGD2, \(^{18}F\)FPPRGD2, and \(^{64}Ga\)Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. *Bioconjug. Chem.* 2011, 22, 2415–2422.

198. Schnell, O.; Krebs, B.; Carlsen, J.; Miederer, I.; Goetz, C.; Goldbrunner, R.H.; Wester, H.J.; Haubner, R.; Popperl, G.; Holtmannspötter, M.; et al. Imaging of integrin αvβ3 expression in patients with malignant glioma by \(^{68}F\)Galacto-RGD positron emission tomography. *Neuro Oncol.* 2009, 11, 861–870.

199. Dumont, R.A.; Hildebrandt, I.; Su, H.; Haubner, R.; Reischl, G.; Czernin, J.G.; Mischel, P.S.; Weber, W.A. Noninvasive imaging of αvβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. *Cancer Res.* 2009, 69, 3173–3179.

200. Yang, M.; Gao, H.; Yan, Y.; Sun, X.; Chen, K.; Quan, Q.; Lang, L.; Kiesewetter, D.; Niu, G.; Chen, X. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. *Eur. J. Nucl. Med. Mol. Imaging* 2011, 38, 1237–1247.

201. Ji, S.; Zheng, Y.; Shao, G.; Zhou, Y.; Liu, S. Integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD therapy. *Theranostics* 2013, 3, 816–830.

202. Shi, J.; Jin, Z.; Liu, X.; Fan, D.; Sun, Y.; Zhao, H.; Zhu, Z.; Liu, Z.; Jia, B.; Wang, F. PET imaging of neovascularization with \(^{68}Ga\)3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy. *Mol. Pharm.* 2014, 11, 3915–3922.

203. Bao, X.; Wang, M.W.; Luo, J.M.; Wang, S.Y.; Zhang, Y.P.; Zhang, Y.J. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters. *Theranostics* 2016, 6, 2084–2098.

204. Minamimoto, R.; Karam, A.; Jamali, M.; Barkhodari, A.; Gambhir, S.S.; Dorigo, O.; Igaru, A. Pilot prospective evaluation of \(^{18}F\)-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2016, 43, 1047–1055.

205. Li, L.; Ma, L.; Shang, D.; Liu, Z.; Yu, Q.; Wang, S.; Teng, X.; Zhang, Q.; Hu, X.; Zhao, W.; et al. Pretreatment PET/CT imaging of angiogenesis based on \(^{18}F\)-RGD tracer uptake may predict antiangiogenic response. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 940–947.

206. Nieblerer, M.; Reuning, U.; Reichart, F.; Notni, J.; Wester, H.J.; Schwaiger, M.; Weinmuller, M.; Rader, A.; Steiger, K.; Kessler, H. Exploring the Role of RGD-Recognizing Integrins in Cancer. *Cancers* 2017, 9, 116.

207. McParland, B.J.; Miller, M.P.; Spinks, T.J.; Kenny, L.M.; Osman, S.; Khela, M.K.; Aboagye, E.; Coombes, R.C.; Hui, A.M.; Cohen, P.S. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide \(^{18}F\)-AH111585 in healthy volunteers. *J. Nucl. Med.* 2008, 49, 1664–1667.

208. Doss, M.; Kolb, H.C.; Zhang, J.J.; Belanger, M.J.; Stubbs, J.B.; Stabin, M.G.; Hostetler, E.D.; Alpaugh, R.K.; von Mehren, M.; Walsh, J.C.; et al. Biodistribution and radiation dosimetry of the integrin marker \(^{18}F\)-RGD-K5 determined from whole-body PET/CT in monkeys and humans. *J. Nucl. Med.* 2012, 53, 787–795.

209. Mitta, E.S.; Goris, M.L.; Igaru, A.H.; Kardan, A.; Burton, L.; Berganos, R.; Chang, E.; Liu, S.; Shen, B.; Chin, F.T.; et al. Pilot pharmacokinetic and dosimetric studies of \(^{18}F\)-FPPRGD2: A PET radiopharmaceutical agent for imaging αvβ3 integrin levels. *Radiology* 2011, 260, 182–191.

210. Zheng, K.; Liang, N.; Zhang, J.; Lang, L.; Zhang, W.; Li, S.; Zhao, J.; Niu, G.; Li, F.; Zhu, Z.; et al. \(^{64}Ga\)NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer. *J. Nucl. Med.* 2015, 56, 1823–1827.

211. Kircher, M.; Herhaus, P.; Schottelius, M.; Buck, A.K.; Werner, R.A.; Wester, H.J.; Keller, U.; Lapa, C. CXCR4-directed theranostics in oncology and inflammation. *Ann. Nucl. Med.* 2018, 32, 503–511.

212. Zlotnik, A.; Burkhardt, A.M.; Homey, B. Homeostatic chemokine receptors and organ-specific metastasis. *Nat. Rev. Immunol.* 2011, 11, 597–606.

213. Domanska, U.M.; Kruizinga, R.C.; Nagengast, W.B.; Timmer-Bosscha, H.; Huls, G.; de Vries, E.G.; W clenkamp, A.M. A review on CXCR4/CXCL12 axis in oncology: No place to hide. *Eur. J. Cancer* 2013, 49, 219–230.

214. Scala, S. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis - Untapped Potential in the Tumor Microenvironment. *Clin. Cancer Res.* 2015, 21, 4278–4285.

215. Wang, Z.; Zhang, M.; Wang, L.; Wang, S.; Kang, F.; Li, G.; Jacobson, O.; Niu, G.; Yang, W.; Wang, J.; et al. Prospective Study of \(^{64}Ga\)NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients. *Theranostics* 2015, 5, 882–889.
216. Vag, T.; Gerngross, C.; Herhaus, P.; Eiber, M.; Philipp-Abbrederis, K.; Graner, F.P.; Ettl, J.; Keller, U.; Wester, H.J.; Schweig, M. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. *J. Nucl. Med.* 2016, 57, 741–746.

217. Werner, R.A.; Kircher, S.; Higuchi, T.; Kircher, M.; Schirbel, A.; Wester, H.J.; Buck, A.K.; Pomper, M.G.; Rowe, S.P.; Lapa, C. CXCR4-Directed Imaging in Solid Tumors. *Front. Oncol.* 2019, 9, 770.

218. Philipp-Abbrederis, K.; Herrmann, K.; Knop, S.; Schottelius, M.; Eiber, M.; Lukekath, K.; Pietschmann, E.; Habringer, S.; Gerngross, C.; Franke, K.; et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. *EMBO Mol. Med.* 2015, 7, 477–487.

219. Lapa, C.; Schredel, M.; Schirbel, A.; Samnick, S.; Kurtom, K.M.; Herrmann, K.; Kropf, S.; Einsele, H.; Buck, A.K.; Wester, H.J.; et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values. *Theranostics* 2017, 7, 205–212.

220. Herhaus, P.; Habringer, S.; Philipp-Abbrederis, K.; Vag, T.; Gerngross, C.; Schottelius, M.; Slotta-Huspenina, J.; Steiger, K.; Alltmann, T.; Weisser, T.; et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. *Haematologica* 2016, 101, 932–940.

221. Mayerhofer, M.E.; Jaeger, U.; Staber, P.; Raderer, M.; Wadsak, W.; Pfaff, S.; Kornauth, C.; Senn, D.; Weber, M.; Wester, H.J.; et al. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. *Invest. Radiol.* 2018, 53, 403–408.

222. Schottelius, M.; Osl, T.; Poschenrieder, A.; Hoffmann, F.; Beyken, S.; Hanscheid, H.; Schirbel, A.; Buck, A.K.; Kropf, S.; Schirbel, M.; et al. [177Lu]pentixafor: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. *Theranostics* 2017, 7, 2350–2362.

223. Lapa, C.; Herrmann, K.; Schirbel, A.; Hanscheid, H.; Lukekath, K.; Schottelius, M.; Kircher, M.; Werner, R.A.; Schredel, M.; Samnick, S.; et al. CXCR4-Directed Endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. *Theranostics* 2017, 7, 1589–1597.

224. Lapa, C.; Hanscheid, H.; Kircher, M.; Schirbel, A.; Wunderlich, G.; Werner, R.A.; Samnick, S.; Kotzerke, J.; Einsele, H.; Buck, A.K.; et al. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. *J. Nucl. Med.* 2019, 60, 60–64.

225. Habringer, S.; Lapa, C.; Herhaus, P.; Schottelius, M.; Istvanffy, R.; Steiger, K.; Slotta-Huspenina, J.; Schirbel, A.; Hanscheid, H.; Kircher, S.; et al. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. *Theranostics* 2018, 8, 369–383.

226. Wester, H.J.; Keller, U.; Schottelius, M.; Beer, A.; Philipp-Abbrederis, K.; Hoffmann, F.; Simecek, J.; Gerngross, C.; Lassmann, M.; Herrmann, K.; et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. *Theranostics* 2015, 5, 618–630.

227. Majkowska-Pilip, A.; Halik, P.K.; Gniazdowska, E. The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy. *Pharmaceuticals* 2019, 11, 443.

228. Krollick, L.; Bruchertseifer, F.; Kunikowska, J.; Koziara, H.; Krollick, B.; Jakucinski, M.; Pawlak, D.; Apostolidis, C.; Mirzadegh, S.; Rola, R.; et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 212Bi-substance P analogue. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 1636–1644.

229. Raderer, M.; Kurtaran, A.; Leimer, M.; Angelberger, P.; Niederle, B.; Vierhapper, H.; Vorbeck, F.; Hejna, M.H.; Scheithauer, W.; Pidlich, J.; et al. Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. *J. Clin. Oncol.* 2000, 18, 1331–1336.

230. Tripathi, S.; Trabulsu, E.J.; Gemella, L.; Kim, S.; McCue, P.; Intenso, C.; Birbe, R.; Gandhe, A.; Kumar, P.; Thakur, M. VPAC1 Targeted 88Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man. *Urology* 2016, 88, 111–118.

231. Thakur, M.L.; Zhang, K.; Berger, A.; Cavanaugh, B.; Kim, S.; Channapa, C.; Frangos, A.J.; Wickstrom, E.; Intenzo, C.M. VPAC1 receptors for imaging breast cancer: A feasibility study. *J. Nucl. Med.* 2013, 54, 1019–1025.

232. Klingler, M.; Hörmann, A.A.; von Guggenberg, E. Cholecystokinin-2 receptor targeting with radiolabeled peptides: Current status and future directions. *Curr. Med. Chem.* 2020. Submitted.

233. Kunikowska, J.; Ziemnicka, K.; Pawlak, D.; Ruchala, M.; Kolasa, A.; Janicka-Jedynska, M.; Wozniak, A.; Mikolajczak, R.; Krollick, L. Medullary thyroid carcinoma - PET/CT imaging with 64Ga-labelled gastrin and somatostatin analogues. *Endocrinol. Pol.* 2016, 67, 68–71.
234. Behe, M.; Behr, T.M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002, 66, 399–418.

235. Sauter, A.W.; Mansi, R.; Hassiepen, U.; Muller, L.; Panigada, T.; Wiehr, S.; Wild, A.M.; Geistlich, S.; Behe, M.; Rottenburger, C.; et al. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 111Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? J. Nucl. Med. 2019, 60, 393–399.

236. Walters, J.; Pop, C.; Scott, F.L.; Drag, M.; Swartz, P.; Mattos, C.; Salvesen, G.S.; Clark, A.C. A constitutively active and uninhibitable case-3 zymogen efficiently induces apoptosis. Biochem. J. 2009, 424, 335–345.

237. Su, H.; Chen, G.; Gangadharmath, U.; Gomez, L.F.; Liang, Q.; Mu, F.; Mocharla, V.P.; Szardenings, A.K.; Walsh, J.C.; Xia, C.F.; et al. Evaluation of [18F]-CP18 as a PET imaging tracer for apoptosis. Mol. Imaging Biol. 2013, 15, 739–747.

238. Doss, M.; Kolb, H.C.; Walsh, J.C.; Mocharla, V.; Fan, H.; Chaudhary, A.; Zhu, Z.; Alpaugh, R.K.; Lango, M.N.; Yu, J.Q. Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers. J. Nucl. Med. 2013, 54, 2087–2092.

239. Ferreira, C.A.; Fuscaldi, I.L.; Townsend, D.M.; Rubello, D.; Barros, A.L.B. Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed. Pharm. 2017, 87, 58–72.

240. Baidoo, K.E.; Lin, K.S.; Zhan, Y.; Finley, P.; Scheffel, U.; Wagner, H.N., Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconj. Chem. 1998, 9, 218–225.

241. Dimitrakopoulos-Stauss, A.; Seiz, M.; Tuettenberg, J.; Schmieder, K.; Eisenhut, M.; Haberkorn, U.; Strauss, L.G. Pharmacokinetic studies of 68Ga-labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: Preliminary results. Clin. Nucl. Med. 2011, 36, 101–108.

242. Wieser, G.; Mansi, R.; Grosu, A.L.; Schultzze-Seemann, W.; Dumont-Walter, R.A.; Meyer, P.T.; Maecke, H.R.; Reubi, J.C.; Weber, W.A. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist - from mice to men. Theranostics 2014, 4, 412–419.

243. Maina, T.; Bergsma, H.; Kulkarni, H.R.; Mueller, D.; Charalambidis, K.; Krenning, E.P.; Nock, B.A.; de Jong, M.; Baum, R.P. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 964–973.

244. Kahkonen, E.; Jambor, I.; Kemppainen, J.; Lehtio, K.; Gronroos, T.J.; Kuisma, A.; Luoto, P.; Siipi, H.J.; Tolvanen, T.; Alanen, K.; et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin. Cancer Res. 2013, 19, 5434–5443.

245. Stoykow, C.; Erbes, T.; Maecke, H.R.; Bulla, S.; Bartholoma, M.; Mayer, S.; Drendel, V.; Bronsert, P.; Werner, M.; Gitsch, G.; et al. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET. Theranostics 2016, 6, 1641–1650.

246. Minamimoto, R.; Hancock, S.; Schneider, B.; Chin, F.T.; Jamali, M.; Loening, A.; Vasanawala, S.; Gambhir, S.S.; Jagaru, A. Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J. Nucl. Med. 2016, 57, 557–562.

247. Ploug, M.; Behrendt, N.; Lober, D.; Dano, K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin. Thromb. Hemost. 1991, 17, 183–193.

248. Persson, M.; Skovgaard, D.; Brandt-Larsen, M.; Christensen, C.; Madsen, J.; Nielsen, C.H.; Thurison, T.; Klausen, T.L.; Holm, S.; Loft, A.; et al. First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics 2015, 5, 1303–1316.

249. Skovgaard, D.; Persson, M.; Kjaer, A. Urokinase Plasminogen Activator Receptor-PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand. PET Clin. 2017, 12, 311–319.

250. Korner, M.; Stockli, M.; Waser, B.; Reubi, J.C. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J. Nucl. Med. 2007, 48, 736–743.

251. Gotthardt, M.; Fischer, M.; Naeher, I.; Holz, J.B.; Jungclas, H.; Fritsch, H.W.; Behe, M.; Goke, B.; Joseph, K.; Behr, T.M. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: Initial experimental results. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 597–606.

252. Hubalewska-Dydejczyk, A.; Sowa-Staszczak, A.; Tomaszuk, M.; Stefanska, A. GLP-1 and exendin-4 for imaging endocrine pancreas. A review. Labelled glucagon-like peptide-1 analogues: Past, present and future. J. Nucl. Med. Mol. Imaging 2015, 59, 152–160.
253. Antwi, K.; Fani, M.; Nicolas, G.; Rottenburger, C.; Heye, T.; Reubi, J.C.; Gloor, B.; Christ, E.; Wild, D. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. *J. Nucl. Med.* **2015**, *56*, 1075–1078.

254. Antwi, K.; Fani, M.; Heye, T.; Nicolas, G.; Rottenburger, C.; Kaul, F.; Merkle, E.; Zech, C.J.; Boll, D.; Vogt, D.R.; et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: Evaluation of diagnostic accuracy in a prospective crossover imaging study. *Eur J. Nucl. Med. Mol. Imaging* **2018**, *45*, 2318–2327.

255. Luo, Y.; Pan, Q.; Yao, S.; Yu, M.; Wu, W.; Xue, H.; Kiesewetter, D.O.; Zhu, Z.; Li, F.; Zhao, Y.; et al. Glucagon-Like Peptide-1 Receptor PET/CT with ⁶⁸Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. *J. Nucl. Med.* **2016**, *57*, 715–720.

256. Boss, M.; Buitinga, M.; Jansen, T.J.; Brom, M.; Visser, E.P.; Gotthardt, M. PET-based dosimetry of [⁶⁸Ga]NODAGA-exendin-4 in humans, a tracer for beta cell imaging. *J. Nucl. Med.* **2019**, doi:10.2967/jnumed.119.228627.

257. Kratochwil, C.; Flechsig, P.; Lindner, T.; Abderrahim, L.; Altmann, A.; Mier, W.; Adeberg, S.; Rathke, H.; Rohrich, M.; Winter, H.; et al. ⁶⁸Ga-FAPi PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. *J. Nucl. Med.* **2019**, *60*, 801–805.

258. Giesel, F.L.; Kratochwil, C.; Lindner, T.; Marschalek, M.M.; Loktev, A.; Lehnert, W.; Debus, J.; Jager, D.; Flechsig, P.; Altmann, A.; et al. ⁶⁸Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. *J. Nucl. Med.* **2019**, *60*, 386–392.

259. Lindner, T.; Loktev, A.; Altmann, A.; Giesel, F.; Kratochwil, C.; Debus, J.; Jager, D.; Mier, W.; Haberkorn, U. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. *J. Nucl. Med.* **2018**, *59*, 1415–1422.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).